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Synthesis and conformational analysis of pentapeptides
containing enantiomerically pure 2,2-disubstituted glycines
Abstract
The synthesis and conformational analysis of model pentapeptides with the sequence
Z-Leu-Aib-Xaa-Gln-Valol is described. These peptides contain two 2,2-disubstituted glycines
(α,α-disubstituted α-amino acids), i.e., Aib (aminoisobutyric acid) and a series of unsymmetrically
substituted, enantiomerically pure amino acids Xaa. These disubstituted amino acids were incorporated
into the model peptides via the ‘azirine/oxazolone method'. Conformational analysis was performed in
solution by means of NMR techniques and in the solid state by X-ray crystallography. Both methods
show that the backbones of thesemodel peptides form helical conformations, as is expected for
2,2-disubstitued glycinecontaining peptides.
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2The synthesis and conformational analysis of model pentapeptides with the sequence
Z-Leu-Aib-Xaa-Gln-Valol is described. These peptides contain two 2,2-disubstituted
glycines (α,α-disubstituted α-amino acids), i.e., Aib (aminoisobutyric acid) and a series of
unsymmetrically substituted, enantiomerically pure amino acids Xaa. These disubstituted
amino acids were incorporated into the model peptides via the ‘azirine/oxazolone method’.
Conformational analysis was performed in solution by means of NMR techniques and in
the solid state by X-ray crystallography. Both methods show that the backbones of these
model peptides form helical conformations, as is expected for 2,2-disubstitued glycine-
containing peptides.
31. Introduction. – Within the last 30 years, 2,2-disubstituted glycines (i.e., α,α-
disubstituted α-amino acids) attracted increasing interest as structural units in biologically
active heterocycles (see, e.g., [1]) and in conformationally restricted peptides (see, e.g.,
[2]). Of special significance are the so-called peptaibols, i.e., peptide antibiotics, which
contain a high proportion of 2,2-dimethylglycine (α-aminoisobutyric acid, Aib) and are
produced by some filamentous fungi [3]. Due to the presence of Aib, these peptides exhibit
helical conformations [4][5]. This structure is essential for their biological activity [6], i.e.,
their ability to form ion channels through membranes [7].
For this reason, several new syntheses of achiral and optically active 2,2-
disubstituted glycines have been reported in recent years [2c][8], as well as new protocols
for the introduction of these sterically congested amino acids into peptides [9 – 11]. In our
laboratory, we have developed the so-called ‘azirine/oxazolone method’ for this purpose
[12][13]. It has been shown that this protocol can be used successfully in the synthesis of
peptaibols and segments thereof [5f][5g][13]. Therefore, a large series of 2H-azirin-3-
amines were prepared as synthons for symmetrical 2,2-disubstituted [14] and heterocyclic
α-amino acids [15], as well as dipeptide synthons [15c][16]. Furthermore, building blocks
for enantiomerically pure 2-methylphenylalanine [17] and 2-ethylalanine (isovaline, Iva)
[18] were obtained after chromatographic separation of the corresponding
diastereoisomeric 2H-azirin-3-amines bearing a chiral residue at the exocyclic N-atom.
Recently, we reported the synthesis of some new optically active 2H-azirin-3-amines 1 as
synthons for enantiomerically pure 2,2-disubstituted glycines by using (R)-[1-(naphthalen-
1-yl)ethyl]amine as the chiral auxiliary [19].
Formulae 1 and 2
4It has been shown that these 2H-azirin-3-amines are suitable for the successful
incorporation of the corresponding enantiomerically pure 2,2-disubstituted glycines into
peptides by use of the ‘azirine/oxazolone method’ [17 – 19]. In the present paper, we
present the synthesis and the results of the conformational analysis of model pentapeptides
2a – g with the sequence Z-Leu-Aib-Xaa-Gln-Valol. With Xaa = Aib or D-Iva, this is the
C-terminal segment of the naturally occurring peptaibol family of trichotoxin A-50 (see
[13e]). As the first examples, we described the preparation of the pentapeptides 2c
containing D- and L-Iva [18].
2. Results and Discussion. – 2.1. Synthesis of the Pentapeptides 2. The model
pentapeptides 2  were synthesized according to Schemes 1 and 2. The N-terminal
tripeptides Z-Leu-Aib-Xaa-NR3R4 3a – g were prepared by using the ‘azirine/oxazolone
method’. First, Z-Leu-OH was coupled with 1a, the synthon for Aib, in Et2O or CH2Cl2 at
room temperature, yielding the dipeptide amide 4, which was hydrolyzed at room
temperature with 3N HCl (H2O/THF 1:1) to give Z-Leu-Aib-OH 5 [19]. The latter was
coupled with the respective azirines 1a – g to yield the tripeptide amides 3a – g (Scheme 1,
Table 1; for the coupling with 1c – g, see [19]).
Scheme 1
Table 1
Subsequent hydrolysis gave the tripeptide acids 6a  – g  (Scheme 2, Table 2). The
structure of (R)-6c was established by X-ray crystallography (Fig. 1). For (R)-6c, the OH
5group forms an intramolecular H-bond with the central amide O-atom, thereby creating a
ten-membered loop and a helical turn within the molecule. This interaction can be
described by the graph set motif [21] of S(10). N(1)–H forms an intermolecular H-bond
with the carboxylic acid carbonyl O-atom of a neighboring molecule, thereby linking the
molecules into extended chains, which run parallel to the [0 1 0] direction and which can
be described by the graph set motif of C(11). N(4)–H forms an intermolecular H-bond with
the amide O-atom of a neighboring molecule, thereby linking the molecules into extended
chains, which run parallel to the [1 0 0] direction and which can be described by the graph
set motif of C(5). The combination of the intermolecular interactions generates a three-
dimensional framework of H-bonded molecules. N(7)–H is not involved in any H-bonding
interactions. The closest acceptor atom is O(12) within the same molecule, but the H···O
and N···O distances of 2.65(3) and 3.330(2) Å are just outside the maximum value (2.6 and




Figure 1. ORTEP Plots [20] of the molecular structures of a) (R)-6c (Z-Leu-Aib-(R)-
Iva-OH), b) (R)-7c (Z-Leu-Aib-(R)-Iva-NHMe), and c) (R)-7d (Z-Leu-Aib-(R)-Val(2Me)-
NHMe) (50% probability ellipsoids; arbitrary numbering of the atoms)
The standard conditions for the hydrolysis of peptide amides with a N-methylanilide
group are 3N HCl (H2O/THF 1:1) at room temperature. However, for the tripeptide amides
of type 3 with NaphthEt(Me)N as the chiral auxiliary group, these conditions have proven
6to be too mild. Therefore, the temperature was increased and the solvent system was
changed to H2O/MeCN 1:1. The optimized new standard conditions were 3 h at 60°.
Interestingly, the coupling of amino acids with a junction at C(3) (i.e., β-branched
amino acids, such as Val(2Me) and Ala(2cPent)) by the reaction of the corresponding
azirine with Z-Leu-Aib-OH proceeded with lower yields than that of amino acids with a
CH2(3) group (linear or γ-branched amino acids; see Table 1). On the other hand, the
hydrolysis gave better yields in the case of β-branched amino acids (Table 2).
During this hydrolysis, a side product 7  with a N-methylamide group, which is
similar to the side products described in [22], was formed in addition to 6 (Scheme 3, Table
2). For example, the hydrolysis of the (S)- and (R)-Iva containing tripeptides (S)- and (R)-
3c gave the side products (S)- and (R)-7c in 30 and 29% yield, respectively. The structures
of the (R)-Iva and (R)-Val(2Me) containing (R)-7c and (R)-7d were determined by X-ray
crystallography (Fig. 1).
Scheme 3
The solid-state structures of (R)-7c and (R)-7d also exhibit the same hydrogen-
bonding motifs and three-dimensional framework as described above for (R)-6c with the
carboxylic acid group now replaced by the amide group involving N(10)–H. N(7)–H is
positioned in approximately the correct position to interact intramolecularly with O(12),
but, again, the H···O and N···O distances of 2.63(2) and 2.78(4) Å, and 3.297(2) and
3.451(3) Å, respectively, are too long to be considered as a significiant N–H…O H-bonding
interactions, particularly in the case of (R)-7d.
7In the crystals of the product (R)-6c and the side product (R)-7c of the hydrolysis of
(R)-3c, as well as the side product (R)-7d of the hydrolysis of (R)-3d, the molecules form a
β-turn of type I' or III', which is in good agreement with the structures of the investigated
pentapeptides (Fig. 1). However, as noted earlier, the interatomic distances for the
intramolecular N–H···O interactions normally associated with such turns (N(10)–H···O(12)
in these structures) are such that the interactions are at best extremely weak hydrogen
bonds.
The coupling of Z-Leu-Aib-OH (5) with (2'R)-1h and (2'S)-1h, i.e., the synthons for
(R)- and (S)-Phe(2Me) [17], and with (2R)-1i and (2S)-1i, the synthons for (R)- and (S)-Iva
[18], to give tripeptide amides of type 3, as well as their hydrolysis to the corresponding
tripeptide acids 6, gave better yields than in the case of 1g and 1c (Table 2), but their chiral
auxiliary groups cannot be as widely used as the NaphthEt(Me)N group.
Formulae 1h and 1i
The C-terminal dipeptide H-Gln-Valol (11) was synthesized via coupling of the 4-
nitrophenyl ester Z-Gln-ONp (8) with L-valinol (Valol, 9) in CH2Cl2 and DMF (active
ester method). The obtained Z-Gln-Valol (10) was deprotected by hydrogenolytic cleavage
of the Z group (H2, Pd/C) in MeOH at room temperature to give 11 (Scheme 2). The
coupling of the tripeptide acids 6 with 11 was carried out by using classical peptide
coupling methods with O -(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HATU) as the coupling reagent (Table 2).
The conformations of the model peptides 2 were investigated in the crystalline state.
For these studies, however, some of the peptides had to be modified by changing the N-
8terminal protecting group, because the Z-protected peptides did not crystallize very well.
The 4-bromobenzoyl group proved to be very suitable for this purpose (Scheme 4). In a
first step, the N-terminus of the pentapeptide 2 was deprotected by treating a solution of 2
in MeOH at room temperature with H2 and Pd/C. After filtration over Celite, the
deprotected pentapeptide 12 was reacted with 4-bromobenzoyl chloride in the presence of
Et3N in CH2Cl2 to give the new pentapeptide 13 (Table 2).
Scheme 4
2.2. Conformational Analysis of the Pentapeptides. The conformations of some
model peptides 2 and 13, respectively, were investigated in the solid state as well as in
solution. X-ray crystal-structure determinations were performed in the cases of 13a
(pBrBz-Leu-Aib-Aib-Gln-Valol), 13b (pBrBz-Leu-Aib-Ac5c-Gln-Valol), (S)-2d (Z-Leu-
Aib-(S)-Val(2Me)-Gln-Valol), (S)-2e (Z-Leu-Aib-(S)-Ala(2cPent)-Gln-Valol), (S)-13f
(pBrBz-Leu-Aib-(S)-Leu(2Me)-Gln-Valol), and (S)-13g (pBrBz-Leu-Aib-(S)-Phe(2Me)-
Gln-Valol) (Fig. 2). All pentapeptides adopt a helical conformation stabilized by
intramolecular H-bonds, which form two β-turns: N(10)–H and N(13)–H interact with the
carbonyl O-atom that is seven atoms back along the peptide backbone. Each of these
interactions has a graph set motif [21] of S(10).
Figure 2. ORTEP Plots [20] of the molecular structures of a) 13a (pBrBz-Leu-Aib-
Aib-Gln-Valol), b) 13b (pBrBz-Leu-Aib-Ac5c-Gln-Valol), c) (S)-2d (Z-Leu-Aib-(S)-
Val(2Me)-Gln-Valol), d) (S)-2e (Z-Leu-Aib-(S)-Ala(2cPent)-Gln-Valol), e) one of the two
symmetry-independent molecules of (S)-13f (pBrBz-Leu-Aib-(S)-Leu(2Me)-Gln-Valol),
9and  f) (S)-13g (pBrBz-Leu-Aib-(S)-Phe(2Me)-Gln-Valol) (50% probability ellipsoids;
arbitrary numbering of the atoms; any solvent molecules and minor disorder components
have been omitted for clarity)
Intermolecular H-bonds also link the molecules in each structure into infinite two-
dimensional networks. In 13a, N(1)–H and N(4)–H form intermolecular H-bonds with,
respectively, the carbonyl O-atom, O(12), and the hydroxy O-atom, O(15), at the opposite
end of a neighboring molecule. These interactions link the peptide molecules into extended
chains which run parallel to the [1 0 1] direction and which can be described by graph set
motifs of C(14). The OH group also forms an intermolecular H-bond with the amide O-
atom, O(33), of the side chain at C(11) of a different neighboring peptide molecule,
thereby linking the molecules into extended chains which run parallel to the [1 0 0]
direction and which can be described by the C(11) motif. The partial occupancy H2O
molecule accepts a H-bond from N(7)–H and also donates a H-bond to O(33) in a different
peptide molecule, thereby linking the peptide and H2O molecules into extended chains
which run parallel to the [0 0 1] direction and which have a C22(12) motif. The NH2 group,
N(33), of the amide side chain forms an intramolecular H-bond with the carbonyl O-atom,
O(16) (S(18) motif), and an intermolecular H-bond with O(9) from a neighboring
molecule. This latter interaction links the the molecules into extended chains which run
parallel to the [1 0 0] direction and which can be described by the C(9) motif. The
combination of all intermolecular interactions links the molecules into infinite two-
dimensional networks, which lie parallel to the (0 1 0) plane.
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The structure of 13b exhibits the same pattern of hydrogen-bonding motifs and two-
dimensional network to that described above for 13a, except that with the absence of a
water molecule, N(7)–H is not involved in a H-bond.
For (S)-2d, the H-atoms of N(37) on the terminal amide side chain are involved in
the same intra- and intermolecular interactions that were described for 13a to give the
S(18) and C(9) motifs. The remaining interactions, however, generate a different pattern:
N(1)–H and N(4)–H form intermolecular H-bonds with the amide O-atom, O(37), of the
terminal amide side chain of the same neighboring molecule. Each of these interactions
links the molecules into extended chains which run parallel to the [0 1 0] direction and
which can be described by graph set motifs of C(16) and C(13), respectively. The OH
group also forms an intermolecular H-bond with the amide O-atom of the terminal amide
side chain, but on a different neighboring molecule. This interaction links the molecules
into extended chains which run parallel to the [1 0 0] direction and have the C(11) motif.
N(7)–H forms an intermolecular H-bond with the hydroxy O-atom of yet another
neighboring molecule, but also links the molecules into extended chains which run parallel
to the [0 1 0] direction and have the C(11) motif. The combination of all intermolecular
interactions links the molecules into infinite two-dimensional networks, which lie parallel
to the (0 0 1) plane.
The structure of (S)-2e exhibits the same pattern of hydrogen-bonding motifs and
two-dimensional network to that described above for (S)-2d.
The structure of (S)-13f has two molecules in the asymmetric unit, A and B. For the
hydrogen-bonding, the molecules of type A interact amongst themselves, as do those of
type B, and the patterns are identical with those described for 13b, except for differences in
the directionality of some chains. The chains involving N(1)–H and N(4)–H of molecule A
11
and those involving the corresponding atoms of molecule B run parallel to the [1 1 0]
direction. The chains involving the OH group, as well as those involving the N–H group of
the terminal amide side chain, run parallel to the [0 1 0] and [1 0 0] directions for
molecules A and B, respectively. Considered overall, the intermolecular H-bonds link the
molecules of (S)-13f into infinite two-dimensional layer networks, where each layer
consists entirely of only one type of symmetry-independent molecule. Thus layers of H-
bonded molecules A and layers of molecules B are stacked in an alternating fashion along
the [001] direction.
For (S)-13g, the NH2 group, N(39), on the terminal amide side chain is involved in
the same intra- and intermolecular interactions that were described for 13a to give the
usual S(18) and C(9) motifs. N(1)–H, and N(7)–H form intermolecular H-bonds with,
respectively, the amide O-atom of the side chain, O(39), and a carbonyl O-atom, O(12), in
two different neighboring peptide molecules. These interactions link the molecules into
extended chains which run parallel to the [0 1 0] direction and which can be described by
graph set motifs of C(16) and C(8), respectively. N(4)–H interacts with O(43) of one of the
two independent MeOH molecules, while O(43) is close enough to O(9) in a different
peptide molecule to be donating a H-bond to the latter atom (the H-atoms of the solvent
molecules could not be located). These interactions link the peptide and MeOH molecules
into extended chains, which run parallel to the [0 1 0] direction and which can be desrcibed
by a graph set motif of C22(10). The hydroxy group, O(15)–H, forms an intermolecular H-
bond with O(44) of the second MeOH molecule, but this solvent molecule does not appear
to act as a H-bond donor. Considered overall, the intermolecular interactions combine to
link the molecules into infinite two-dimensional networks, which lie parallel to the (0 0 1)
plane.
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In Tables 3 and 4, the torsion angles φi+1, ψ i+1, φ i+2, and ψ i+2 of the β-turns are
summarized. The values show that two consecutive β-turns of type III/I are formed for
13a, 13b, (S)-2d, (S)-2e, and (S)-13f, whereas in the case of (S)-13g two β-turns of type
III/III are observed. The III/III combination can be considered as an incipient 310-helix.
Table 3
Table 4
The results described above are in good agreement with previously reported results
obtained for Aib [23 – 29], Ac5c [14][30][31], Val(2Me) [32], Leu(2Me) [33], and
Phe(2Me) [34 – 36] containing oligopeptides.
The conformation of the model peptide (S)-2g was also investigated in solution by
means of NMR techniques. An easy way is the observation of the signals of the amide H-
atoms under different conditions. Their chemical shifts show a significantly different
behaviour when they are involved in an intramolecular H-bond, than when exposed to the
solvent or forming intermolecular H-bonds. Intramolecularly bound NH atoms are much
less influenced by temperature changes [14] or by addition of polar solvents or radicals
[37].
For (S)-2g, the 1H-NMR spectra were measured at different temperatures. Although
it was not possible to assign every signal in the NMR spectrum, two strongly temperature
dependent NH signals were found, i.e., the signals for the amide H-atoms of Leu and Aib,
which are not involved in the H-bonding pattern of the incipient 310-helix. One other signal
was also temperature dependent, but to a much lesser extent, i.e., one of the amide protons
of the Gln side chain. This result is in agreement with the X-ray crystal structure of (S)-
13
13g, i.e., the corresponding pBrBz-protected derivative of (S)-2g, where one amide H-atom
of the Gln side chain is intramolecularly involved in a H-bond with the C=O group of the
N-terminal protecting pBrBz-group, and the other amide NH-atom of the Gln side chain is
exposed to the environment and should show a significant temperature dependence. All
other amide H-atoms of (S)-2g did not show a significant temperature-dependence (Fig. 3).
The NH-atom of Phe(2Me) could not be observed and is supposed to lie in the region of
the aromatic H-atoms.
Figure 3
As can be seen in Fig. 3, the temperature dependence of the amide H-atoms is linear.
In order to compare the effects, the temperature coefficients were calculated and are shown
in Table 5.
Table 5
As only the amide H-atoms of Leu and Aib, but not of Phe(2Me), Gln(2Me), and
Valol are temperature dependent, it is likely that the incipient 310-helix, which was
observed for (S)-13g in the solid state, is also the dominant conformation in solution.
In conclusion, it has been shown that the model pentapeptides of the type Z-Leu-Aib-
Xaa-Gln-Valol, with Xaa = 2,2-disubstituted glycine, can be prepared conveniently by
using the ‘azirine/oxazolone method’. They adopt a helical conformation in the solid state
and in solution; the results from crystallographic and NMR-investigations are in good
agreement with each other.
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Experimental Part
1. General. See [19]. 1H- (600 MHz) and 13C-NMR (150.9 MHz) Spectra: Bruker
AMX-600 instrument.
2. Preparation of H-Gln-Valol (11). 2.1. N-[(Benzyloxy)carbonyl]-glutaminyl-valinol
(Z-Gln-Valol; 10). To a soln. of L-valinol (9, 0.66 g, 6.40 mmol) in abs. CH2Cl2 (50 ml), a
soln. of Z-Gln-ONp (8, 2.83 g, 7.10 mmol) in abs. DMF (25 ml) was added slowly at 0°.
After 6 h, the gel-like precipitate was diluted with CHCl3 (25 ml) and stirred for 18 h at r.t.,
then, additional CHCl3 (50 ml) was added. After 2 h, the precipitate was filtered, washed
with AcOEt/CHCl3 1:1 and Et2O. Recrystallization from EtOH yielded 1.717 g (73%) of
10. Colorless crystals. M.p. 186.6 – 187.0°. Rf (CH2Cl2/MeOH 10:1) 0.20. IR: 3430s,
3300s, 3200m, 3080w, 3060w, 2960m, 2930m, 2870m, 1680s, 1660s, 1645s, 1555s, 1535s,
1505m, 1470m, 1465m, 1445m, 1415m, 1390m, 1370m, 1350m, 1330m, 1260s, 1245s,
1190w, 1140w, 1060m, 1040m, 1020m, 995w, 940w, 910w, 880w, 855w, 770w, 745m. 1H-
NMR (CD3OD): 7.35 – 7.3 (m, 5 arom. H); 5.08 (br. s, PhCH2O); 4.14 (dd, J = 8.5, 5.8,
CH(2) of Gln); 3.7 – 3.55 (m, CH(2) and CH2(1) of Valol); 2.31 (t, J = 7.5, CH2(4) of Gln);
2.15 – 1.8 (m, CH(3) of Valol, CH2(3) of Gln); 0.93, 0.89 (2d, J = 6.8, 2 Me(4) of Valol).
13C-NMR (CD3OD): 177.8 (s, CONH2); 174.3 (s, CONH); 158.3 (s, OCONH); 138.1 (s, 1
15
arom. C); 129.4, 128.9, 128.8 (3d, 5 arom. CH); 67.6 (t, PhCH2O); 63.0 (t, C(1) of Valol);
58.0, 56.0 (2d, C(2) of Gln, C(2) of Valol); 32.5 (t, C(4) of Gln); 30.0 (d, C(3) of Valol);
29.1 (t, C(3) of Gln); 19.9, 18.8 (2q, 2 Me(4) of Valol). ESI-MS (MeOH): 404 (31, [M +
K]+), 388 (100, [M  + Na]+). Anal. calc. for C18H27N3O5 (365.43): C 59.16, H 7.45, N
11.50; found: C 59.27, H 7.71, N 11.54.
2.2. Glutaminyl-valinol (H-Gln-Valol; 11). A soln. of 10 (14.970 g, 40.97 mmol) and
Pd/C (10% on activated charcoal, 0.550 g) in MeOH (950 ml) was treated with H2 for 18 h
at r.t. The mixture was filtered over Celite, and the filtrate was evaporated: 9.419 g (99%)
of 11. Colorless solid. M.p. 134.5 – 135.2°. IR: 3350s, 3280s, 3200s, 3110s, 2950s, 2930s,
2870m, 1690s, 1680s, 1670s, 1645s, 1630s, 1615s, 1565s, 1550s, 1515m, 1505m, 1465m,
1450m, 1415s, 1385m, 1370m, 1350m, 1335m, 1310m, 1280m, 1245m, 1200w, 1150m,
1080m, 1070m, 1025m, 975m, 950m, 875w, 845w, 815w, 780w, 770w, 715m. 1H-NMR:
3.7 – 3.5 (m, CH2(1) of Valol, CH(2) of Gln); 3.4 – 3.3 (m, CH(2) of Valol); 2.35 – 2.3 (m,
CH2(4) of Gln); 2.0 – 1.75 (m, CH2(3) of Gln, CH(3) of Valol); 0.96, 0.93 (2d, J = 6.9, 6.8,
2 Me of Valol). 13C-NMR: 178.3, 177.1 (2s, 2 CONH); 63.0 (t, C(1) of Valol); 57.9, 55.7
(2d, C(2) of Gln, C(2) of Valol); 32.7, 32.5 (2t, C(3), C(4) of Gln); 30.0 (d, C(3) of Valol);
19.8, 18.8 (2q, 2 Me of Valol). CI-MS (NH3): 233 (11), 232 (100, [M + 1]
+), 229 (10), 215
(20), 214 (12), 129 (5), 104 (7), 101 (6).
3. Peptides with Xaa = Aib. 3.1. Benzyl [(S)-1-({[1,1-Dimethyl-2-({1,1-dimethyl-2-
[methyl(phenyl)amino]-2-oxoethyl}amino)-2-oxoethyl]amino}carbonyl)-3-methylbutyl]-
carbamate (Z-Leu-Aib-Aib-N(Me)Ph; 3a). To a soln. of N-[(Benzyloxy)carbonyl]leucyl-α-
aminoisobutyric acid (Z-Leu-Aib-OH [19]; 5, 1.152 g, 3.29 mmol) in abs. CH2Cl2 (25 ml),
2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine (1a [38], 0.610 g, 3.50 mmol) was added at
0°. The soln. was stirred for 23 h at r.t. The mixture was washed with 2N HCl, 1N NaOH-
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soln., and sat. aq. NaCl-soln., dried (MgSO4), and evaporated: 1.645 g (95%) of 3a.
Colorless solid. M.p. 57.1 – 57.8°. Rf (CH2Cl2/MeOH 10:1) 0.51; Rf (CH2Cl2/MeOH 20:1)
0.18. IR: 3310s, 3060m, 3030m, 2955s, 2870m, 2140w, 1950w, 1880w, 1820w, 1705vs,
1690vs, 1680vs, 1660vs, 1640vs, 1595s, 1540 – 1520vs, 1495vs, 1470s, 1455s, 1390s,
1365s, 1315m, 1265 – 1240s, 1220s, 1170m, 1120m, 1090s, 1070m, 1045m, 1030m,
1005w, 965w, 920w, 910w, 875w, 840w, 825w, 770m, 740m, 705s. 1H-NMR (CD3OD): 7.4
– 7.2 (m, 10 arom. H); 5.15, 5.09 (AB, J = 12.8, PhCH2O); 4.00 (t, J = 7.5, CH(2) of Leu);
3.25 (br. s, MeN); 1.7 – 1.65 (m, CH(4) of Leu); 1.55 – 1.5 (m, CH2(3) of Leu); 1.47, 1.44,
1.41, 1.38 (4s, 4 Me of 2 Aib); 0.96, 0.93 (2d, J = 6.7, 6.5, 2 Me of Leu). 13C-NMR
(CD3OD): 176.2, 175.6, 175.2 (3s, 3 CONH); 158.8 (s, OCONH); 146.9 (s, 1 arom. CN);
138.5 (s, 1 arom. C); 130.4, 129.7, 129.1, 128.5 (4d, 10 arom. CH); 67.6 (t, PhCH2O);
58.7, 58.2 (2s, 2 C(2) of 2 Aib); 55.7 (d, C(2) of Leu); 41.6 (t, C(3) of Leu); 41.3 (q, MeN);
26.6, 26.4, 26.0, 24.7 (d, 3q, C(4) of Leu, 4 Me of 2 Aib); 23.4, 22.4 (2q, 2 Me of Leu).
ESI-MS (NaI): 547 (100, [M + Na]+). Anal. calc. for C29H40N4O5·H2O (530.67): C 65.64,
H 7.72, N 10.56; found: C 65.90, H 7.56, N 10.73.
3.2. N-[(Benzyloxy)carbonyl]-leucyl-α-aminoisobutyryl-α-aminoisobutyric Acid (Z-
Leu-Aib-Aib-OH; 6a). A soln. of 3a (1.373 g, 2.62 mmol) in 3N HCl (THF/H2O 1:1, 40 ml)
was stirred for 2 h at r.t. Thereby, a colorless precipitate was formed. Then, 2N HCl (40
ml) was added, and the mixture was extracted with CH2Cl2. During this operation the
precipitate dissolved. The org. soln. was dried (MgSO4) and evaporated. Washing of the
residue with AcOEt yielded 1.005 g (88%) of 6a. Colorless solid. M.p. 192 – 193°. Rf
(CH2Cl2/MeOH 10:1) 0.18 – 0.07. IR: 3385m, 3330s, 3290s, 3060w, 3030w, 2980w,
2950m, 2865w, 1740s, 1705vs, 1660s, 1550m, 1525s, 1500m, 1470w, 1455w, 1440w,
1385m, 1365w, 1315s, 1295m, 1270s, 1245s, 1220m, 1175w, 1130w, 1120w, 1080w,
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1045m, 1030w, 990w, 970w, 945w, 910w, 850w, 785w, 765w, 755w, 740w, 730w. 1H-
NMR (CD3OD): 7.35 – 7.25 (m, 5 arom. H); 5.13, 5.08 (AB, J =12.6, PhCH2O); 4.02 (t, J
= 7.5, CH(2) of Leu); 1.7 – 1.65 (m, CH(4) of Leu); 1.52 (dd, J = 7.8, 7.2, CH2(3) of Leu);
1.44, 1.43, 1.42, 1.40 (4s, 4 Me of 2 Aib); 0.96, 0.93 (2d, J = 6.5, 2 Me of Leu). 13C-NMR
(CD3OD): 178.0, 175.9, 175.1 (3s, COOH, 2 CONH); 158.7 (s, OCONH); 138.3 (s, 1
arom. C); 129.5, 129.0, 128.6 (3d, 5 arom. CH); 67.6 (t, PhCH2O); 57.9, 57.1 (2s, 2 C(2) of
2 Aib); 55.5 (d, C(2) of Leu); 41.5 (t, C(3) of Leu); 25.9 (d, C(4) of Leu); 26.1, 25.5, 24.7,
24.6, 23.3, 22.2 (6q, 4 Me of 2 Aib, 2 Me of Leu). ESI-MS (NaI): 458 (100, [M + Na]+).
Anal. calc. for C22H33N3O6 (435.51): C 60.67, H 7.64, N 9.65; found: C 60.55, H 7.63, N
9.59.
3.3. N-[(Benzyloxy)carbonyl]-leucyl-α -aminoisobutyryl-α-aminoisobutyryl-glu-
taminyl-valinol (Z-Leu-Aib-Aib-Gln-Valol, 2a). To a soln. of 6a (100 mg, 0.230 mmol)
and Et3N (70 mg, 0.690 mmol) in abs. DMF (2.5 ml) at r.t., HATU (87 mg, 0.230 mmol)
was added. After 5 min, HOBt (35 mg, 0.23 mmol), and after a further 5 min, 11 (53 mg,
0.230 mmol) was added and the mixture was stirred for 19 h at r.t., and evaporated. The
residue was dissolved in AcOEt, washed with 1N HCl and 1N NaOH-soln., dried (MgSO4)
and evaporated. Recrystallization from AcOEt/hexane yielded 114 mg (77%) 2a. Colorless
crystals. M.p. 170 – 172°. R f (CH2Cl2/MeOH 10:1) 0.16. IR: 3310s, 3030w, 2960m,
2870w, 1655vs, 1535s, 1470w, 1455w, 1385w, 1365w, 1335w, 1310w, 1265m, 1230w,
1170w, 1120w, 1040w, 1030w, 925w, 850w, 790w, 740w. 1H-NMR (CD3OD): 7.92 (d, J =
6.9, NH); 7.46 (s, NH); 7.35 – 7.25 (m, 5 arom. H); 5.13, 5.10 (AB, J = 12.7, PhCH2O);
4.15 – 4.05 (m, CH(2) of Gln, CH(2) of Leu); 3.7 – 3.65 (m, CH(2) and CH2(1) of Valol);
2.4 – 2.35 (m, CH2(4) of Gln); 2.25 – 2.2 (m, CH2(3) of Gln); 1.9 – 1.85 (m, CH(3) of
Valol); 1.75 – 1.7 (m, CH(4) of Leu); 1.6 – 1.55 (m, CH2(3) of Leu); 1.4 – 1.35 (m, 4 Me of
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2 Aib); 1.0 – 0.9 (m, 2 Me of Leu, 2 Me of Valol). 13C-NMR (CD3OD): 177.9, 177.8,
176.8, 176.1, 174.4 (5s, 5 CONH); 158.9 (s, OCONH); 138.4 (s, 1 arom. C); 129.6, 129.0,
128.6 (3d, 5 arom. CH); 67.8 (t, PhCH2O); 63.6 (t, C(1) of Valol); 58.6 (d, C(2) of Gln);
58.0, 57.8 (2s, 2 C(2) of 2 Aib); 56.2, 55.9 (2d, C(2) of Valol, C(2) of Leu); 41.4 (t, C(3) of
Leu); 33.5 (t, C(4) of Gln); 30.1 (d, C(3) of Valol); 28.5 (t, C(3) of Gln); 25.9 (d, C(4) of
Leu); 26.9, 25.8, 24.6, 24.2, 23.3, 22.2 (6q, 4 Me of 2 Aib, 2 Me of Leu); 20.1, 19.4 (2q, 2
Me of Valol). ESI-MS (MeOH): 687 (25, [M + K]+), 672 (94, [M + Na]+), 650 (100, [M +
1]+). Anal. calc. for C32H52N6O8·H2O (666.82): C 57.64, H 8.01, H 12.60; found: C 57.38,




Valol; 13a). A soln. of 2a (71 mg, 0.109 mmol) and Pd/C (10% on activated charcoal, 7
mg) in MeOH (5 ml) was treated with H2 for 1.5 h at r.t. The mixture was filtered over
cotton wool, and the filtrate was evaporated. The residue (58 mg) was dissolved in CH2Cl2
(5 ml), and Et3N (30 mg, 0.297 mmol) and 4-bromobenzoylchloride (35 mg, 0.159 mmol)
were added. A precipitate formed while stirring for 30 min at r.t. The mixture was washed
with 2N HCl and 1N NaOH. The precipitate dissolved after addition of a small amount of
MeOH. The org. soln. was dried (MgSO4) and evaporated. The residue (59 mg, 78%, 13a)
was recrystallized from MeOH, CH2Cl2, Et2O and petroleum ether. Colorless crystals. M.p.
232.9 – 233.8°. Rf (CH2Cl2/MeOH 10:1) 0.15. IR: 3650w, 3420s, 3340vs, 3280vs, 3060w,
2980m, 2980s, 2960s, 2870m, 2540w, 2490w, 2440w, 2400w, 1675vs, 1660vs, 1650vs,
1595s, 1540vs, 1485s, 1465s, 1455s, 1440s, 1415m, 1390s, 1365s, 1340m, 1300s, 1235m,
1200m, 1175m, 1140m, 1070m, 1010m, 980w, 940w, 925w, 900w, 870w, 860w, 825w,
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790w, 765w. 1H-NMR (CD3OD): 7.81, 7.62 (AA'BB', J = 8.5, 4 arom. H); 4.55 – 4.5 (m,
CH(2) of Gln); 4.15 – 4.1 (m, CH(2) of Leu); 3.62 (br. s, CH2(1) and CH(2) of Valol); 2.35
– 2.3 (m, CH2(4) of Gln); 2.25 – 2.0 (m, CH2(3) of Gln); 1.85 – 1.65 (m, CH(3) of Valol,
CH(4) and CH2(3) of Leu); 1.45 – 1.4 (m, 4 Me of 2 Aib); 1.01, 0.99, 0.87, 0.79 (4d, J =
5.9, 6.0, 6.7, 6.8, 2 Me of Leu, 2 Me of Valol). 13C-NMR (CD3OD): 178.0, 177.8, 176.9,
175.6, 174.3 (5s, 5 CONH); 169.6 (s, 1 CO (amide, pBrBz)); 134.0 (s, 1 arom. C); 132.8,
130.6 (2d, 4 arom. CH); 127.4 (s, 1 arom. CBr); 63.5 (t, C(1) of Valol); 58.6 (d, C(2) of
Gln); 58.1, 57.9 (2s, 2 C(2) of 2 Aib); 56.1, 54.5 (2d, C(2) of Valol, C(2) of Leu); 41.2 (t,
C(3) of Leu); 33.6 (t, C(4) of Gln); 30.0 (d, C(3) of Valol); 26.6 (t, C(3) of Gln); 26.1 (d,
C(4) of Leu); 28.5, 25.3, 25.1, 24.6, 23.4, 22.1 (6q, 4 Me of 2 Aib, 2 Me of Leu); 20.1,
19.3 (2q, 2 Me of Valol). ESI-MS (TFA): 737 (6, [M + K]+, 81Br), 721 (39, [M + Na]+,
81Br), 699 (100, [M + 1]+, 81Br), 681 (13, [M – OH]+, 81Br), 596 (18, [M – Valol]+, 81Br),
468 (15, [M – Gln-Valol]+, 81Br). Anal. calc. for C31H49BrN6O7 (697.67): C 53.37, H 7.08,
N 12.05; found: C 53.26, H 7.12, N 11.99.
Crystals suitable for an X-ray crystal-structure determination were obtained from a
mixture of MeOH, CH2Cl2, Et2O, and petroleum ether by slow evaporation of the solvent.
4. Peptides with Xaa = Ac5c. 4.1. Benzyl {(S)-1-[({1,1-Dimethyl-2-[(1-{[methyl(phe-
nyl)amino]carbonyl}cyclopentyl)amino]-2-oxoethyl}amino)carbonyl]-3-methylbutyl}-
carbamate (Z-Leu-Aib-Ac5c-N(Me)Ph; 3b). As described for 3a, with 5 [19] (0.705 g, 2.01
mmol) in abs. CH2Cl2 (20 ml), N-methyl-N-phenyl-1-azaspiro[2.4]hept-1-en-2-amine (1b
[39], 0.439 g (containing 12.5% amide), 1.92 mmol): 1.030 g (97%) of 3b. Colorless solid.
M.p. 67.7 – 69.1°. Rf (CH2Cl2/MeOH 10:1) 0.52; Rf (CH2Cl2/MeOH 20:1) 0.16. IR: 3310s,
3060m, 3030m, 2955s, 2870m, 1950w, 1810w, 1705vs, 1660vs, 1595s, 1520vs, 1495vs,
1470s, 1455s, 1380s, 1310m, 1260vs, 1220s, 1170m, 1120m, 1045s, 1030m, 1005w, 985w,
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955w, 910w, 840w, 765m, 735m, 700s. 1H-NMR (CD3OD): 7.4 – 7.2 (m, 10 arom. H);
5.13, 5.11 (AB, J = 12.8, PhCH2O); 4.00 (t, J = 7.5, CH2(2) of Leu); 3.22 (br. s, MeN); 2.4
– 2.35, 2.3 – 2.2, 2.2 – 1.95 (3m, 4 H of Ac5c); 1.75 – 1.65 (m, CH(4) of Leu, 4 H of Ac5c);
1.6 – 1.5 (m, CH2(3) of Leu); 1.47, 1.40 (2s, 2 Me of Aib); 0.96, 0.93 (2d, J = 6.6, 2 Me of
Leu). 13C-NMR (CD3OD): 176.3, 175.6, 175.3 (3s, 3 CONH); 159.0 (s, OCONH); 147.0
(s, 1 arom. CN); 138.6 (s, 1 arom. C); 130.5, 129.8, 129.3, 128.7, 128.5, 128.3 (6d, 10
arom. CH); 68.8 (s, C(2) of Ac5c); 67.8 (t, PhCH2O); 58.4 (s, C(2) of Aib); 55.8 (d, C(2) of
Leu); 41.7 (t, C(3) of Leu); 41.1 (q, MeN); 38.7, 38.2 (2t, 2 C(3) of Ac5c); 26.1 (d, C(4) of
Leu); 25.7, 25.6 (2t, 2 C(4) of Ac5c); 26.8, 24.9, 23.5, 22.5 (4q, 2 Me of Aib, 2 Me of Leu).
ESI-MS (NaI): 573 (100, [M + Na]+). Anal. calc. for C31H42N4O5·0.33 H2O (556.71): C
66.88, H 7.72, N 10.06; found: C 67.12, H 7.64, N 10.02.
4.2.  1-({2-[((S)-2-{[(Benzyloxy)carbonyl]amino}-4-methyl-1-oxopentyl)amino]-2-
methyl-1-oxopropyl}amino)cyclopentan-1-carboxylic Acid (Z-Leu-Aib-Ac5c-OH; 6b). As
described for 6a, with 3b (750 mg, 1.36 mmol), 3N HCl (THF/H2O 1:1, 30 ml), 2.5 h at
r.t., 2N HCl (15 ml), recrystallization from AcOEt/hexane: 566 mg (90%) of 6b. Colorless
crystals. M.p. 175.0 – 176.5°. Rf (CH2Cl2/MeOH 10:1) 0.13. IR: 3300s, 3060m, 3030m,
2955s, 2870m, 1740s, 1720vs, 1695vs, 1660vs, 1590w, 1530vs, 1470m, 1455s, 1410m,
1390m, 1365m, 1345m, 1330m, 1315m, 1250s, 1175m, 1120m, 1050m, 1030m, 1005w,
950w, 910w, 770w, 735m. 1H-NMR (CD3OD): 7.49 (br. s, NH); 7.35 – 7.3 (m, 5 arom. H);
5.15 – 5.05 (m, PhCH2O); 4.02 (t, J = 7.5, CH(2) of Leu); 2.25 – 2.0 (m, 4 H of Ac5c); 1.7
– 1.65 (m, CH(4) of Leu, 4 H of Ac5c); 1.52 (dd, J = 7.5, 6.2, CH2(3) of Leu); 1.43 (br. s, 2
Me of Aib); 0.96, 0.93 (2d, J = 6.7, 2 Me of Leu). 13C-NMR (CD3OD): 177.8, 176.4, 175.0
(3s, COOH, 2 CONH); 158.7 (s, OCONH); 138.2 (s, 1 arom. C); 129.5, 129.1, 128.7 (3d, 5
arom. CH); 67.7 (t, PhCH2O); 67.3 (s, C(2) of Ac5c); 57.8 (s, C(2) of Aib); 55.5 (d, C(2) of
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Leu); 41.5 (t, C(3) of Leu); 38.1, 37.7 (2t, 2 C(3) of Ac5c); 25.9 (d, C(4) of Leu); 25.6 (t, 2
C(4) of Ac5c); 26.0, 24.7, 23.3, 22.2 (4q, 2 Me of Aib, 2 Me of Leu). ESI-MS (NaI): 506
(4, [M + 2 Na – 1]+), 484 (100, [M + Na]+). Anal. calc. for C24H35N3O6·0.33 H2O (467.57):
C 61.65, H 7.69, N 8.99; found: C 61.95, H 7.52, N 9.03.
4.3. Benzyl ((S )-1-{[(2-{[1-({[4-Amino-(S)-1-({[(S)-1-(hydroxymethyl)-2-methyl-
propyl]amino}carbonyl)-4-oxobutyl]amino}carbonyl)cyclopentyl]amino}-1,1-dimethyl-2-
oxoethyl)amino]carbonyl}-3-methylbutyl)carbamate (Z-Leu-Aib-Ac5c-Gln-Valol; 2b). A
soln. of 6b (239 mg, 0.518 mmol) and Et3N (108 mg, 1.069 mmol) in abs. DMF (3.5 ml)
was stirred for 10 min at 0°, then, HATU (217 mg, 0.571 mmol) was added. After stirring
at 0° for 8 min, 11 (132 mg, 0.57 mmol) was added and the mixture was stirred for 90 min
at 0° and 40 h at r.t. The solvent was evaporated, the residue dissolved in AcOEt and a
small amount of MeOH, washed with 2N HCl and 1N NaOH-soln., dried (MgSO4), and
evaporated. CC (CH2Cl2/MeOH 10:1) yielded 304 mg (87%) of 2b. Colorless solid. M.p.
97.6 – 98.1°. Rf (CH2Cl2/MeOH 10:1) 0.17. IR: 3300s, 3035w, 2960m, 2870w, 1665vs,
1535s, 1470m, 1455m, 1405w, 1390m, 1365w, 1315m, 1270m, 1220m, 1170w, 1130w,
1120w, 1045w, 1030w, 960w, 925w, 910w, 890w, 850w, 820w, 790w, 740w. 1H-NMR
(CD3OD): 7.35 – 7.25 (m, 5 arom. H); 5.16, 5.11 (AB, J = 12.7, PhCH2O); 4.16 (t, J = 7.3,
CH(2) of Gln); 4.02 (t, J = 7.5, CH(2) of Leu); 3.7 – 3.6 (m, CH(2) and CH2(1) of Valol);
2.4 – 2.3 (m, CH2(4) of Gln, CH(3) of Valol); 2.25 – 2.15 (m, CH2(3) of Gln); 2.0 – 1.85
(m, 4 H of Ac5c); 1.75 – 1.55 (m, 4 H of Ac5c, CH(4) and CH2(3) of Leu); 1.40, 1.38 (2s, 2
Me of Aib); 1.0 – 0.9 (m, 2 Me of Leu, 2 Me of Valol). 13C-NMR (CD3OD): 177.8, 177.4,
177.2, 176.1, 174.4 (5s, 5 CONH); 159.1 (s, OCONH); 138.4 (s, 1 arom. C); 129.6, 129.0,
128.4 (3d, 5 arom. CH); 68.1 (s, C(2) of Ac5c); 67.8 (t, PhCH2O); 63.6 (t, C(1) of Valol);
58.5 (d, C(2) of Gln); 57.8 (s, C(2) of Aib); 56.2, 56.1 (2d, C(2) of Leu, C(2) of Valol);
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41.3, 38.8, 37.4 (3t, C(3) of Leu, 2 C(3) of Ac5c); 33.4 (t, C(4) of Gln); 30.1 (d, C(3) of
Valol); 28.5 (t, C(3) of Gln); 25.9 (d, C(4) of Leu); 25.7, 25.6 (2t, 2 C(4) of Ac5c); 24.7,
23.2, 22.4 (3q, 2 Me of Aib, 2 Me of Leu); 20.1, 19.4 (2q, 2 Me of Valol). ESI-MS (TFA):
698 (20, [M + Na]+), 675 (100, [M + 1]+), 657 (15, [M – OH]+), 572 (19, [M – Valol]+),
444 (22, [M – Gln-Valol]+). Anal. calc. for C34H54N6O8·0.5 H2O (683.85): C 59.72, H 8.11,
N 12.29; found: C 59.48, H 8.20, N 12.28.
4.4. N- ( ( S )-1-{[(2-{[1-({[4-Amino-(S)-1-({[(S)-1-(hydroxymethyl)-2-methylpro-
pyl]amino}carbonyl)-4-oxobutyl]amino}carbonyl)cyclopentyl]amino}-1,1-dimethyl-2-
oxoethyl)amino]carbonyl}-3-methylbutyl) 4-Bromobenzamide (pBrBz-Leu-Aib-Ac5c-Gln-
Valol; 13b). As described for 13a, with 2b (83 mg, 0.123 mmol), Pd/C (10% on activated
charcoal, 9 mg), MeOH (5 ml), and H2, 2 h at r.t., filtration over Celite, with CH2Cl2 (5
ml), Et3N (18 mg, 0.178 mmol), 4-bromobenzoylchloride (27 mg, 0.123 mmol), 1.5 h at
r.t.; purification with CC (CH2Cl2/MeOH 10:1): 76 mg (85%) of 13b. Colorless solid. M.p.
242.8 – 243.6°. Rf (CH2Cl2/MeOH 10:1) 0.18. IR: 3405s, 3340vs, 3250s, 3060w, 2960s,
2875m, 1675vs, 1655vs, 1590s, 1540vs, 1485s, 1470m, 1455s, 1440m, 1410m, 1390m,
1360m, 1340m, 1315m, 1295m, 1255m, 1220m, 1180m, 1170m, 1150w, 1140w, 1130w,
1110w, 1095w, 1070w, 1020w, 1010m, 980w, 940w, 920w, 870w, 850w, 820w, 790w,
760w. 1H-NMR (CD3OD): 7.82, 7.63 (AA'BB', J = 8.4, 8.5, 4 arom. H); 4.5 – 4.45 (m,
CH(2) of Gln); 4.15 – 4.1 (m, CH(2) of Leu); 3.65 – 3.55 (m, CH(2) and CH2(1) of Valol);
2.35 – 2.3 (m, CH2(4) of Gln); 2.3 – 2.0 (m, CH2(3) of Gln, CH(3) of Valol, 2 H of Ac5c);
1.9 – 1.85 (m, CH(4) of Leu); 1.85 – 1.65 (m, CH2(3) of Leu, 6 H of Ac5c); 1.43 (s, 2 Me
of Aib); 1.02, 0.99, 0.86, 0.78 (4d, J = 6.0, 6.2, 6.8, 6.8, 2 Me of Leu, 2 Me of Valol). 13C-
NMR (CD3OD): 177.8, 177.4, 177.2, 175.7, 174.2 (5s, 5 CONH); 169.8 (s, 1 CO (amide,
pBrBz)); 133.9 (s, 1 arom. C); 132.8, 130.6 (2d, 4 arom. CH); 127.5 (s, 1 arom. CBr); 68.2
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(s, C(2) of Ac5c); 63.5 (t, C(1) of Valol); 58.4 (d, C(2) of Gln); 57.9 (s, C(2) of Aib); 55.9,
55.0 (2d, C(2) of Leu, C(2) of Valol); 41.0, 38.5, 37.8 (3t, C(3) of Leu, 2 C(3) of Ac5c);
33.4 (t, C(4) of Gln); 30.0 (d, C(3) of Valol); 28.3 (t, C(3) of Gln); 26.1 (d, C(4) of Leu);
25.7 (t, 2 C(4) of Ac5c); 25.7, 25.3, 23.3, 22.3 (4q, 2 Me of Aib, 2 Me of Leu); 20.0, 19.3
(2q, 2 Me of Valol). ESI-MS (TFA): 763 (6, [M + K]+, 81Br), 745 (35, [M + Na]+, 81Br),
725 (100, [M + 1]+, 81Br), 707 (22, [M – OH]+, 81Br), 622 (31, [M – Valol]+, 81Br), 494 (33,
[M – Gln-Valol]+, 81Br). Anal. calc. for C33H51N6O7: C 54.77, H 7.10, N 11.61; found: C
54.49, H 7.20, N 11.76.
Recrystallization from AcOEt, MeOH, and petroleum ether gave crystals suitable for
an X-ray crystal-structure determination.
5. Tripeptide with (S)-Iva. N-[(Benzyloxy)carbonyl]-leucyl-α-aminoisobutyryl-(S)-
isovaline (Z-Leu-Aib-(S)-Iva-OH; (S)-6c). A soln. of (S)-3c [19] (438 mg, 0.710 mmol) in
3N HCl (MeCN/H2O 1:1, 10 ml) was stirred for 3 h at 60°. The mixture was extracted with
CH2Cl2, dried (MgSO4), and evaporated. Prep. TLC (CH2Cl2/MeOH 10:1) yielded 118 mg
(37%) of (S)-6c and 98 mg (30%) of benzyl [(S)-1-({[1,1-dimethyl-2-({(S)-1-methyl-1-
[(methylamino)carbonyl]propyl}amino)-2-oxoethyl]amino}carbonyl)-3-methylbutyl]carb-
amate (Z-Leu-Aib-(S)-Iva-NHMe; (S)-7c).
Data of (S)-6c: Colorless solid. M.p. 78 – 80°. Rf (CH2Cl2/MeOH 10:1) 0.06. IR:
3320m, 2960m, 1710s, 1660s, 1525s, 1455m, 1385m, 1365w, 1315w, 1245m, 1165m,
1130w, 1050m, 945w, 800w, 780w, 740w, 700w. 1H-NMR: 7.35 – 7.3 (m, 5 arom. H); 7.18
(br. s, NH); 7.08 (br. s, NH); 5.75 (d, J = 5.7, NH of Leu); 5.10 (br., PhCH2O); 4.15 – 4.1
(m, CH(2) of Leu); 2.05 – 1.9 (m, CH2(3) of Iva or Leu); 1.7 – 1.5 (m, CH2(3) of Leu or
Iva, Me(3) of Iva, 2 Me of Aib, CH(4) of Leu); 0.95 – 0.9 (m, 2 Me of Leu); 0.82 (t, J =
7.4, MeCH2 of Iva). 
13C-NMR: 173.8, 172.9 (2s, 2 CONH, COOH); 156.7 (s, OCONH);
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136.0 (s, 1 arom. C); 128.5, 128.2, 127.8 (3d, 5 arom. CH); 67.1 (t, PhCH2O); 60.3, 57.2
(2s, C(2) of Iva, C(2) of Aib); 54.3 (d, C(2) of Leu); 40.7, 29.1 (2t, C(3) of Leu, C(3) of
Iva); 24.6 (d, C(4) of Leu); 25.1, 22.8, 22.0, 21.7, 8.0 (5q, 2 Me of Aib, Me(3) of Iva,
Me(4) of Iva, 2 Me of Leu). ESI-MS (MeOH): 504 (15, [M + Na + MeOH]+), 488 (50, [M
+ K]+), 472 (62, [M + Na]+), 450 (100, [M + 1]+), 432 (14, [M – OH]+), 333 (10, [M –
Iva]+). Anal. calc. for C23H35N3O6 (449.55): C 61.45, H 7.85, N 9.35; found: C 61.58, H
7.65, N 9.34.
Data of (S)-7c: Colorless solid. M.p. 204 – 205°. Rf (CH2Cl2/MeOH 10:1) 0.43. IR:
3385m, 3314s, 3017w, 2969m, 2871w, 1703vs, 1648vs, 1523vs, 1462m, 1442w, 1410w,
1385w, 1372w, 1362w, 1341w, 1312w, 1291w, 1271w, 1243s, 1216m, 1175w, 1134w,
1118w, 1083w, 1047m, 1030w, 969w, 944w, 916w, 846w, 804w, 790w, 749w, 737w, 699w,
670w, 630w. 1H-NMR (CD3OD): 7.35 – 7.3 (m, 5 arom. H); 5.07 (s, PhCH2O); 4.04 (dd, J
= 8.9, 6.1, CH(2) of Leu); 2.69 (s, MeN); 2.2 – 2.05, 1.85 – 1.65, 1.65 – 1.45 (3m, CH2(3)
of Iva, CH2(3) of Leu, CH(4) of Leu); 1.42, 1.39, 1.33 (3s, Me(3) of Iva, 2 Me of Aib);
0.97, 0.95 (2d, J = 6.8, 6.7, 2 Me of Leu); 0.78 (t, J = 7.5, Me(4) of Iva). 13C-NMR
(CD3OD): ca. 177.5, 176, 175.5 (3s, 3 CONH); ca. 159 (s, OCONH); ca. 138 (s, 1 arom.
C); 129.4, 128.9, 128.5 (3d, 5 arom. CH); 67.5 (t, PhCH2O); 61.4, 58.0 (2s, C(2) of Iva,
C(2) of Aib); 55.2 (d, C(2) of Leu); 41.2, 29.4 (2t, C(3) of Leu, C(3) of Iva); 25.7 (d, C(4)
of Leu); 26.4, 26.1, 24.4, 23.2, 23.0, 22.0, 8.0 (7q, MeN, 2 Me of Aib, Me(3) of Iva, Me(4)
of Iva, 2 Me of Leu). CI-MS (NH3): 464 (16), 463 (56, [M + 1]
+), 432 (14, [M – HNMe]+),
356 (20), 355 (10, [M – OBn]+). Anal. calc. for C24H38N4O5·0.2 H2O (466.19): C 61.83, H
8.30, N 12.02; found: C 61.85, H 8.24, N 11.94.
6. Tripeptide with (R)-Iva. N-[(Benzyloxy)carbonyl]-leucyl-α-aminoisobutyryl-(R)-
isovaline (Z-Leu-Aib-(R)-Iva-OH; (R)-6c). 6.1. Hydrolysis of (R)-3c. As described for (S)-
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6c, with (R)-3c [19] (437 mg, 0.710 mmol), and 3N HCl (MeCN/H2O 1:1, 8 ml), 3 h at 60°,
CC (CH2Cl2/MeOH 100:2, then 100:3, 20:1, 10:1) and prep. TLC (CH2Cl2/MeOH 10:1):
123 mg (39%) of (R)-6c (colorless solid) and 95 mg (29%) of benzyl [(S)-1-({[1,1-
dimethyl-2-({(R)-1-methyl-1-[(methylamino)carbonyl]propyl}amino)-2-oxoethyl]amino}-
carbonyl)-3-methylbutyl]carbamate (Z-Leu-Aib-(R)-Iva-NHMe; (R)-7c, colorless solid).
Crystals of (R)-7c suitable for an X-ray crystal-structure determination were grown from
MeOH/CH2Cl2.
6.2. Hydrolysis of (R)-3i. As described for (S)-6c, with (R)-3i [18] (56 mg, 0.099
mmol), and 3N HCl (MeCN/H2O 1:1, 0.5 ml), 3 h at 60°, prep. TLC (CH2Cl2/MeOH 10:1):
37 mg (84%) of (R)-6c.
Data of (R)-6c: Colorless solid. M.p. 69 – 71°. Rf (CH2Cl2/MeOH 10:1) 0.06. IR:
3393s, 3344s, 3280s 3065m, 2955s, 1738vs, 1706vs, 1664vs, 1522vs, 1456m, 1388m,
1376m, 1329m, 1272vs, 1244s, 1216s, 1172w, 1135w, 1046s, 975w, 914w, 848w, 788w,
733w, 697m. 1H-NMR: 7.4 – 7.3 (m, 5 arom. H); 7.16 (br. s, NH); 6.95 (br., NH); 5.60 (br.,
NH); 5.11 (br., PhCH2O); 4.11 (br., CH(2) of Leu); 2.05 – 1.9 (m, CH2(3) of Iva or Leu);
1.7 – 1.5 (m, CH2(3) of Leu or Iva, Me(3) of Iva, 2 Me of Aib, CH(4) of Leu); 0.95 – 0.9
(m, 2 Me of Leu); 0.83 (t, J = 7.3, MeCH2 of Iva). 
13C-NMR: ca. 177, 173 (2s, 2 CONH,
COOH); ca. 157 (s, OCONH); ca. 136 (s, 1 arom. C); 128.5, 128.2, 127.9 (3d, 5 arom.
CH); 67.2 (t, PhCH2O); 60.4, ca. 58 (2s, C(2) of Iva, C(2) of Aib); 54.2 (d, C(2) of Leu);
40.8, 29.6 (2t, C(3) of Leu, C(3) of Iva); 24.6 (d, C(4) of Leu); 25.3, 22.8, 21.9, 7.9 (4q, 2
Me of Aib, Me(3) of Iva, Me(4) of Iva, 2 Me of Leu). ESI-MS (MeOH, NaI): 953 (10, [2M
+ Na + MeOH]+), 921 (14, [2M + Na]+), 473 (16), 472 (59, [M + Na]+), 451 (26), 450 (100,
[M + 1]+), 432 (10, [M – OH]+). Anal. calc. for C23H35N3O6·0.33 H2O (455.56): C 60.64, H
7.89, N 9.22; found: C 60.59, H 7.61, N 9.02.
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Crystals suitable for an X-ray crystal-stucture determination were grown from
MeOH.
Data of (R)-7c: M.p. 212.8 – 213.6°. R f (CH2Cl2/MeOH 10:1) 0.40. IR: 3385m,
3314s, 3017w, 2969s, 2954m, 2871w, 2513w, 2483w, 1703s, 1648vs, 1523s, 1462m,
1406w, 1385w, 1372w, 1361w, 1349w, 1312w, 1291m, 1272m, 1244m, 1216m, 1175w,
1134w, 1118w, 1047m, 1030w, 968w, 944w, 917w, 848w, 789w, 748w, 699w, 629w. 1H-
NMR (CD3OD): 7.5 (br., NH); 7.35 – 7.3 (m, 5 arom. H); 7.13 (br. s, NH); 5.10, 5.06 (AB,
J = 12.6, PhCH2O); 4.05 (dd, J = 8.7, 6.4, CH(2) of Leu); 2.70 (s, MeN); 1.9 – 1.85 (m, 1
H of CH2(3) of Iva, CH2(3) of Leu, or CH(4) of Leu); 1.75 – 1.65 (m, 2 H of CH2(3) of Iva,
CH2(3) of Leu, or CH(4) of Leu); 1.55 – 1.5 (m, 2 H of CH2(3) of Iva, CH2(3) of Leu, or
CH(4) of Leu); 1.41, 1.40, 1.39 (3s, Me(3) of Iva, 2 Me of Aib); 0.96 (2d, J = 6.4, 6.6, 2
Me of Leu); 0.79 (t, J = 7.5, Me(4) of Iva). 13C-NMR (CD3OD): 177.1, 175.9, 175.3 (3s, 3
CONH); 158.3 (s, OCONH); 137.9 (s, 1 arom. C); 129.3, 128.8, 128.3 (3d, 5 arom. CH);
67.4 (t, PhCH2O); 61.1, 57.8 (2s, C(2) of Iva, C(2) of Aib); 55.1 (d, C(2) of Leu); 41.1,
31.6 (2t, C(3) of Leu, C(3) of Iva); 25.6 (d, C(4) of Leu); 26.4, 25.9, 24.5, 23.1, 22.1, 21.7,
8.1 (7q, MeN, 2 Me of Aib, Me(3) of Iva, Me(4) of Iva, 2 Me of Leu). CI-MS (NH3): 465
(10), 464 (45), 463 (100, [M  + 1]+), 433 (19), 432 (56, [M  – NHMe]+), 355 (5, [M  –
OBn]+), 329 (8, [M – benzyloxycarbonyl + 2]+). Anal. calc. for C24H38N4O5·0.25 H2O
(466.64): C 61.71, H 8.31, N 11.99; found: C 61.74, H 8.05, N 11.91.
7. Peptides with Xaa = (S)-Val(2Me). 7.1. (S)-2-({2-[((S)-2-{[(Benzyloxy)carbonyl]-
amino}-4-methyl-1-oxopentyl)amino]-2-methyl-1-oxopropyl}amino)-2,3-dimethylbutanoic
Acid (Z-Leu-Aib-(S)-Val(2Me)-OH;  (S)-6d). As described for (S)-6c, with (S)-3d [19]
(1.480 g, 2.35 mmol), 3N HCl (MeCN/H2O 1:1, 20 ml), 90 min at 60°; CC (CH2Cl2/MeOH
100:2, then 100:3) and prep. TLC (CH2Cl2/MeOH 10:1): 711 mg (65%) of (S)-6d and 239
27
mg (21%) of benzyl [(S)-1-({[1,1-dimethyl-2-({(S)-1,2-dimethyl-1-[(methylamino)-
carbonyl]propyl}amino)-2-oxoethyl]amino}carbonyl)-3-methylbutyl]carbamate  (Z-Leu-
Aib-(S)-Val(2Me)-NHMe; (S)-7d).
Data of (S)-6d: Colorless solid. M.p. 69 – 70°. Rf (CH2Cl2/MeOH 10:1) 0.15. IR:
3320s, 2970s, 1715s, 1670s, 1535s, 1460m, 1390m, 1370m, 1250s, 1180m, 1165m, 1130w,
1050m, 955w, 785w, 745w, 705m. 1H-NMR: 7.35 – 7.3 (m, 5 arom. H, NH); 6.90 (br. s,
NH); 5.62 (d, J = 6.5, NH); 5.10 (br., PhCH2O); 4.15 – 4.1 (m, CH(2) of Leu); 2.35 – 2.3
(m, CH(3) of Val(2Me)); 1.7 – 1.4 (m, CH2(3) and CH(4) of Leu, 2 Me of Aib, Me(3) of
Val(2Me)); 0.95 – 0.85 (m, 2 Me of Leu, 2 Me(4) of Val(2Me)). 13C-NMR: 175.4, 174.5,
173.0 (3s, 2 CONH, COOH); 156.5 (s, OCONH); 136.0 (s, 1 arom. C); 128.5, 128.2, 127.9
(3d, 5 arom. CH); 67.1 (t, PhCH2O); 63.5, 57.5 (2s, C(2) of Val(2Me), C(2) of Aib); 54.3
(d, C(2) of Leu); 40.7 (t, C(3) of Leu); 33.5, 24.7 (2d, C(3) of Val(2Me), C(4) of Leu);
25.1, 24.9, 22.8, 21.7, 18.0, 17.3, 16.9 (7q, 2 Me of Aib, Me(3) and 2 Me(4) of Val(2Me),
2 Me of Leu). ESI-MS (MeOH): 502 (11, [M + K]+), 486 (94, [M + Na]+), 464 (100, [M +
1]+), 446 (28, [M – OH]+), 333 (13, [M – Val(2Me)]+). Anal. calc. for C24H37N3O6·0.33
H2O (469.58): C 61.39, H 7.94, N 8.95; found: C 61.34, H 8.17, N 8.79.
Data of (S)-7d: Colorless solid. M.p. 67 – 69°. Rf (CH2Cl2/MeOH 10:1) 0.41. IR:
3304s, 3035w, 2964s, 2873w, 1708s, 1664vs, 1540s, 1455m, 1411w, 1370w, 1311w,
1267s, 1222m, 1173w , 1120w, 1054m , 915w , 788w , 742w, 696w , 620w . 1H-NMR
(CD3OD): 7.35 – 7.25 (m, 5 arom. H); 5.13, 5.09 (AB, J = 12.6, PhCH2O); 4.05 (dd, J =
8.7, 6.2, CH(2) of Leu); 2.71 (s, MeN); 2.1 – 1.95, 1.8 – 1.65, 1.65 – 1.45 (3m, CH(3) of
Val(2Me), CH2(3) of Leu, CH(4) of Leu); 1.39 (s, Me(3) of Val(2Me), 2 Me of Aib); 0.96,
0.94, 0.89 (3d, J = 7.5, 7.0, 6.8, 2 Me of Leu, 2 Me(4) of Val(2Me)). 13C-NMR (CD3OD):
ca. 176.5, ca. 176, ca. 175.5 (3s, 3 CONH); ca. 159 (s, OCONH); 138.2 (s, 1 arom. C);
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129.4, 129.0, 128.5 (3d, 5 arom. CH); 67.6 (t, PhCH2O); 61.4, 58.0 (2s, C(2) of Val(2Me),
C(2) of Aib); 55.6 (d, C(2) of Leu); 41.6 (t, C(3) of Leu); 36.5 (d, C(3) of Val(2Me)); 25.8
(d, C(4) of Leu); 26.4, 25.9, 24.6, 23.2, 21.9, 18.5, 17.8, 17.7 (8q, MeN, 2 Me of Aib,
Me(3) of Val(2Me), 2 Me(4) of Val(2Me), 2 Me of Leu). ESI-MS (MeOH, NaI): 499 (100,
[M + Na]+). Anal. calc. for C25H40N4O5·0.25 H2O (481.12): C 62.41, H 8.48, N 11.65;
found: C 62.50, H 8.47, N 11.47.
7.2. Benzyl ((S )-1-{[(2-{[(S)-1-({[4-Amino-(S)-1-({[(S)-1-(hydroxymethyl)-2-me-
thylpropyl]amino}carbonyl)-4-oxobutyl]amino}carbonyl)-1,2-dimethylpropyl]amino}-1,1-
dimethyl-2-oxoethyl)amino]carbonyl}-3-methylbutyl)carbamate (Z-Leu-Aib-(S)-Val(2Me)-
Gln-Valol; (S)-2d). To a soln. of (S)-6d (176 mg, 0.380 mmol) and Et3N (115 mg, 1.14
mmol) in abs. DMF (2.5 ml) at r.t., HATU (144 mg, 0.380 mmol) was added. After 2 min,
HOBt (57 mg, 0.380 mmol), and after further 4 min, 11 (88 mg, 0.38 mmol) were added,
and the mixure was stirred for 91 h at r.t. and evaporated. The residue was dissolved in
AcOEt, washed with 1N HCl and 1N NaOH-soln., dried (MgSO4), and evaporated. From
the residue, crystals formed over night. They were separated and dried. The filtrate was
purified by prep. TLC (CH2Cl2/MeOH 10:1). Total yield of (S)-2d: 94 mg (37%).
Colorless solid. M.p. 202 – 203°. Rf (CH2Cl2/MeOH 10:1) 0.17. IR: 3455m, 3335s, 3213m,
2957m, 2870m, 2369w, 2352w, 1706s, 1659s, 1615m, 1540s, 1456m, 1389m, 1274m,
1262m, 1171m, 1129w, 1043w, 698m. 1H-NMR: 7.93 (br. s, NH); 7.80 (br., NH); 7.35 –
7.25 (m, 5 arom. H); 7.05 (br., NH); 6.93 (br. s, NH); 6.73 (br., NH); 5.58 (br., NH); 5.15,
5.12 (AB, J = 12.7, PhCH2O); 4.15 – 4.0, 3.85 – 3.8, 3.7 – 3.55 (3m, CH(2) of Gln, CH(2)
of Leu, CH(2) and CH2(1) of Valol); 3.19 (br., OH); 2.45 – 2.2 (m, CH2(4) and CH2(3) of
Gln); 1.95 – 1.9, 1.8 – 1.6 (2m, CH2(3) of Leu, CH(3) of Valol, CH(3) of Val(2Me)); 1.4 –
1.35 (m, CH(4) of Leu, 2 Me of Aib, Me(3) of Val(2Me)); 1.0 – 0.85 (m, 2 Me of Valol, 2
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Me(4) of Val(2Me), 2 Me of Leu). 13C-NMR: 175.1, 174.9, 172.8 (3s, 5 CONH); 157.1 (s,
OCONH); 136.5 (s, 1 arom. C); 128.5, 128.0, 127.4 (3d, 5 arom. CH); 66.8, 63.5 (2t,
PhCH2O, C(1) of Valol); 63.0, 57.0 (2s, C(2) of Aib, C(2) of Val(2Me)); 57.5, 55.8 (2d,
C(2) of Gln, C(2) of Valol, C(2) of Leu); 39.9, 32.7, 27.7 (3t, C(4) and C(3) of Gln, C(3) of
Leu); 35.6, 28.9, 24.6 (3d, C(3) of Valol, C(3) of Val(2Me), C(4) of Leu); 26.6, 22.9, 22.7,
21.5, 19.5, 19.2, 17.3, 17.2, 17.1 (9q, 2 Me of Aib, Me(3) of Val(2Me), 2 Me of Valol, 2
Me(4) of Val(2Me), 2 Me of Leu). ESI-MS (MeOH, AcOH): 699 (9, [M + Na]+), 680 (9),
679 (36), 678 (100, [M + 1]+). Anal. calc. for C34H56N6O8·0.33 H2O (682.86): C 59.80, H
8.30, N 12.31; found: C 59.67, H 8.53, N 12.13.
8. Peptides with Xaa = (R)-Val(2Me). 8.1. (R)-2-({2-[((S)-2-{[(Benzyloxy)carbonyl]-
amino}-4-methyl-1-oxopentyl)amino]-2-methyl-1-oxopropyl}amino)-2,3-dimethylbutanoic
Acid (Z-Leu-Aib-(R)-Val(2Me)-OH; (R)-6d). As described for (S)-6c, with (R)-3d [19]
(1.394 mg, 2.21 mmol), 3N HCl (MeCN/H2O 1:1, 20 ml), 2 h at 60°; CC (CH2Cl2/MeOH




Data of (R)-6d: Colorless solid. M.p. 163 – 164°. Rf (CH2Cl2/MeOH 10:1) 0.20. IR:
3320s, 2970m, 1720s, 1670s, 1540s, 1460m, 1390m, 1370m, 1250m, 1180m, 1165m,
1130w, 1050m, 745w, 707w. 1H-NMR: 7.4 – 7.3 (m, 5 arom. H); 7.03 (br., NH); 5.57 (d, J
= 6.6, NH); 5.10 (br., PhCH2O); 4.15 – 4.05 (m, CH(2) of Leu); 2.3 – 2.25 (m, CH(3) of
Val(2Me)); 1.7 – 1.4 (m, CH2(3) and CH(4) of Leu, 2 Me of Aib, Me(3) of Val(2Me));
0.95 – 0.9 (m, 2 Me of Leu, 2 Me(4) of Val(2Me)). 13C-NMR: ca. 175, 174, 173 (3s, 2
CONH, COOH); ca. 157 (s, OCONH); 135.8 (s, 1 arom. C); 128.5, 128.3, 127.9 (3d, 5
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arom. CH); 67.2 (t, PhCH2O); 63.7, 57.6 (2s, C(2) of Val(2Me), C(2) of Aib); 54.0 (d, C(2)
of Leu); 41.0 (t, C(3) of Leu); 33.3, 24.6 (2d, C(3) of Val(2Me), C(4) of Leu); 25.6, 24.5,
22.8, 21.8, 17.9, 17.2, 16.7 (7q, 2 Me of Aib, Me(3) and 2 Me(4) of Val(2Me), 2 Me of
Leu). ESI-MS (MeOH): 502 (12, [M + K]+), 486 (90, [M + Na]+), 464 (100, [M + 1]+), 446
(15, [M  – OH]+), 333 (16, [M  – Val(2Me)]+). Anal. calc. for C24H37N3O6·0.33 H2O
(469.58): C 61.37, H 8.09, N 8.95; found: C 61.38, H 8.01, N 8.53.
Data of (R)-7d: Colorless solid. M.p. 195.8 – 196.9°. Rf (CH2Cl2/MeOH 10:1) 0.41.
IR: 3287s, 2966m, 2875w, 1703s, 1673vs, 1518s, 1463w, 1412w, 1362w, 1315w, 1271s,
1234m, 1216m, 1175w, 1117w, 1047m, 1029w, 971w, 943w, 914w, 789w, 747w, 699w,
625w. 1H-NMR (CD3OD): 7.4 – 7.25 (m, 5 arom. H); 5.09, 5.05 (AB, J = 12.5, PhCH2O);
4.09 (dd, J = 8.9, 6.1, CH(2) of Leu); 2.69 (s, MeN); 2.05 – 1.9, 1.75 – 1.45 (2m, CH(3) of
Val(2Me), CH2(3) of Leu, CH(4) of Leu); 1.40 (s, Me(3) of Val(2Me), 2 Me of Aib); 0.97,
0.95, 0.91, 0.79 (4d, J = 7.7, 7.0, 6.8, 6.8, 2 Me of Leu, 2 Me(4) of Val(2Me)). 13C-NMR
(CD3OD): ca. 176.5, 176.2, ca. 175.5 (3s, 3 CONH); ca. 159 (s, OCONH); 138.1 (s, 1
arom. C); 129.4, 128.9, 128.4 (3d, 5 arom. CH); 67.3 (t, PhCH2O); 64.1, 58.1 (2s, C(2) of
Val(2Me), C(2) of Aib); 54.9 (d, C(2) of Leu); 41.4 (t, C(3) of Leu); 36.7 (d, C(3) of
Val(2Me)); 25.7 (d, C(4) of Leu); 26.9, 26.4, 23.5, 23.1, 22.1, 17.6, 17.5, 17.2 (8q, MeN, 2
Me of Aib, Me(3) of Val(2Me), 2 Me(4) of Val(2Me), 2 Me of Leu). ESI-MS (MeOH,
NaI): 499 (100, [M + Na]+). Anal. calc. for C25H40N4O5·0.33 H2O (482.63): C 62.22, H
8.49, N 11.61; found: C 62.12, H 8.47, N 12.06.
Crystals suitable for X-ray-analysis were grown from CD3OD.




Val(2Me)-Gln-Valol; (R)-2d). As described for 2a, with (R)-6d (599 mg, 1.29 mmol), Et3N
(0.54 ml, 392 mg, 3.90 mmol), abs. DMF (13 ml), and HATU (491 mg, 1.29 mmol), 3 min
at r.t., HOBt (196 mg, 1.30 mmol), 4 min at r.t., 11 (301 mg, 1.30 mmol), 65 h at r.t.; CC
(CH2Cl2/MeOH 20:1): 357 mg (41%) of (R)-2d and 202 mg of starting material (R)-6d
(34%). Colorless solid. M.p. 110 – 111°. Rf (CH2Cl2/MeOH 10:1) 0.15. IR: 3416s, 2962s,
1664s, 1534s, 1456m, 1388m, 1375m, 1264m, 1179w, 1122w, 1049w, 849s, 740m, 698m.
1H-NMR: 7.70 (br., 2 NH); 7.35 – 7.3 (m, 5 arom. H); 6.94 (br., NH); 6.84 (br. s, NH);
6.79 (br., NH); 6.22 (br., NH); 5.15 – 5.05 (m, PhCH2O); 4.25 – 4.15, 4.15 – 4.05, 3.75 –
3.55 (3m, CH(2) of Gln, CH(2) of Leu, CH(2) and CH2(1) of Valol); 2.45 – 2.15 (m,
CH2(4) and CH2(3) of Gln); 1.8 – 1.55 (m , CH2(3) of Leu, CH(3) of Valol, CH(3) of
Val(2Me)); 1.45 – 1.25 (m, CH(4) of Leu, 2 Me of Aib, Me(3) of Val(2Me)); 1.0 – 0.75
(m, 2 Me of Valol, 2 Me(4) of Val(2Me), 2 Me of Leu). 13C-NMR: ca. 176, 174.3, 174.1,
172.7 (4s, 5 CONH); ca. 157 (s, OCONH); 136.4 (s, 1 arom. C); 128.5, 128.1, 127.5 (3d, 5
arom. CH); 66.8, 63.2 (2t, PhCH2O, C(1) of Valol); 62.2, 57.2 (2s, C(2) of Aib, C(2) of
Val(2Me)); 57.1, 54.9, 54.4 (3d, C(2) of Gln, C(2) of Valol, C(2) of Leu); 40.1, 32.3, 27.3
(3t, C(4) and C(3) of Gln, C(3) of Leu); 33.4, 28.9, 24.6 (3d, C(3) of Valol, C(3) of
Val(2Me), C(4) of Leu); 22.7, 21.8, 19.5, 19.1, 17.8, 17.7 (6q, 2 Me of Aib, Me(3) of
Val(2Me), 2 Me of Valol, 2 Me(4) of Val(2Me), 2 Me of Leu). ESI-MS (MeOH, AcOH):
701 (11), 700 (46), 699 (100, [M  + Na]+), 586 (10, [M  – C7H7 + 1]
+). Anal. calc. for
C34H56N6O8·0.5 H2O (685.86): C 59.54, H 8.38, N 12.25; found: C 59.25, H 8.52, N 12.16.
9. Peptides with Xaa = (S)-Ala(2cPent). 9.1. (S)-2-({2-[((S)-2-{[(Benzyloxy)carbo-
nyl]amino}-4-methyl-1-oxopentyl)amino]-2-methyl-1-oxopropyl}amino)-2-cyclopentyl-
propanoic Acid (Z-Leu-Aib-(S)-Ala(2cPent)-OH; (S)-6e). As described for (S)-6c, with (S)-
3e [19] (98 mg, 0.149 mmol), 3N HCl (MeCN/H2O 1:1, 1.5 ml), 3 h at 60°; prep. TLC
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(CH2Cl2/MeOH 10:1): 54 mg (74%) of (S)-6e. Colorless solid. M.p. 79 – 81°. R f
(CH2Cl2/MeOH 10:1) 0.26. IR: 3321m, 2956s, 2871m, 1706vs, 1668vs, 1526vs, 1455m,
1386w, 1249m, 1047w, 738w. 1H-NMR: 7.35 – 7.25 (m, 5 arom. H); 7.21 (br. s, NH); 7.06
(br. s, NH); 5.80 (br., NH); 5.10 (br. s, PhCH2O); 4.15 – 4.1 (m, CH(2) of Leu); 2.45 – 2.35
(m, CH(3) of Ala(2cPent)); 1.75 – 1.35 (m, CH2(3) and CH(4) of Leu, 2 Me of Aib, Me of
Ala(2cPent), 4 CH2 of Ala(2cPent)); 0.95 – 0.9 (m, 2 Me of Leu). 
13C-NMR: 175.7, 174.0,
173.2 (3s, 2 CONH, COOH); 156.5 (s, OCONH); 136.1 (s, 1 arom. C); 128.4, 128.1, 127.7
(3d, 5 arom. CH); 67.0 (t, PhCH2O); 61.8, 57.4 (2s, C(2) of Ala(2cPent), C(2) of Aib); 54.3
(d, C(2) of Leu); 46.1 (d, C(3) of Ala(2cPent)); 40.7 (t, C(3) of Leu); 27.0, 26.8, 25.3 (3t, 4
CH2 of cPent); 25.0 (q, MeN); 24.6 (d, C(4) of Leu); 22.8, 21.7, 19.5, 14.0 (4q, 2 Me of
Aib, Me of Ala(2cPent), 2 Me of Leu). ESI-MS (MeOH): 512 (100, [M + Na]+), 490 (52,
[M + 1]+), 307 (13). Anal. calc. for C26H39N3O6 (489.61): C 63.78, H 8.03, N 8.58; found:
C 63.80, H 8.12, N 8.24.
9 . 2 .  Benzyl  {(S)-1-[({2-[((S)-2-{[4-Amino-(S)-1-({[(S)-1-(hydroxymethyl)-2-
methylpropyl]amino}carbonyl)-4-oxobutyl]amino}-1-cyclopentyl-1-methyl-2-oxo-
ethyl)amino]-1,1-dimethyl-2-oxoethyl}amino)carbonyl]-3-methylbutyl}carbamate (Z-Leu-
Aib-(S)-Ala(2cPent)-Gln-Valol; (S)-2e). As described for 2a, with (S)-6e (149 mg, 0.304
mmol), Et3N (0.1 ml, 72.6 mg, 0.720 mmol), abs. DMF (2 ml), and HATU (117 mg, 0.308
mmol), 2 min at 0°, HOAt (0.5M soln. in DMF, 0.6 ml, 0.3 mmol), 3 min at 0°, 11 (70.5
mg, 0.305 mmol), 20 min at 0° and 70 h at r.t.; after the washing procedure described for
2a, crystals suitable for X-ray crystal-structure determination were obtained. Prep. TLC
(CH2Cl2/MeOH 10:1) of the rest; total yield: 93 mg (43%) of (S)-2e. Colorless solid. M.p.
208.0 – 209.1°. Rf (CH2Cl2/MeOH 10:1) 0.37. 
1H-NMR (CD3OD): 7.35 – 7.3 (m, 5 arom.
H); 5.25 – 5.05 (m, PhCH2O); 4.1 – 4.05, 3.7 – 3.65 (2m, CH(2) of Gln, CH(2) of Leu,
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CH(2) and CH2(1) of Valol); 2.45 – 2.3, 2.25 – 2.15, 1.95 – 1.85, 1.8 – 1.5 (4m, CH2(4)
and CH2(3) of Gln, CH2(3) of Leu, 4 CH2 of Ala(2cPent), CH(4) of Leu, CH(3) of Valol,
CH(3) of Ala(2cPent)); 1.44 (s, Me of Ala(2cPent)); 1.39 (s, 2 Me of Aib); 0.95 – 0.9 (m, 2
Me of Valol, 2 Me of Leu). 13C-NMR (CD3OD): 177.4, ca. 176.5, 176.2, 174.5 (4s, 5
CONH); 158.7 (s, OCONH); ca. 143 (s, 1 arom. C); 129.4, 128.9, 128.4 (3d, 5 arom. CH);
67.5, 63.6 (2t, PhCH2O, C(1) of Valol); 63.0, 58.0 (2s, C(2) of Aib, C(2) of Ala(2cPent));
58.6, 56.6, 55.7 (3d , C(2) of Gln, C(2) of Valol, C(2) of Leu); 49.1 (d , C(3) of
Ala(2cPent)); 41.8, 33.6, 28.4, 28.1, 27.8, 26.1, 26.1 (7t, 4 CH2 of Ala(2cPent), C(4) and
C(3) of Gln, C(3) of Leu); 29.9, 25.8 (2d, C(3) of Valol, C(4) of Leu); 26.4, 23.9, 23.2,
21.9, 20.0, 19.7, 19.3 (7q, 2 Me of Aib, Me of Ala(2cPent), 2 Me of Valol, 2 Me of Leu).
ESI-MS (MeOH, NaI): 725 (100, [M  + Na]+), 703 (100, [M  + 1]+). Anal. calc. for
C36H58N6O8 (702.89): C 61.52, H 8.32, N 11.96; found: C 61.33, H 8.44, N 12.04.
10. Peptides with Xaa = (R)-Ala(2cPent). 10.1. (R)-2-({2-[((S)-2-{[(Benzyloxy)-
carbonyl]amino}-4-methyl-1-oxopentyl)amino]-2-methyl-1-oxopropyl}amino)-2-
cyclopentylpropanoic Acid (Z-Leu-Aib-(R)-Ala(2cPent)-OH; (S)-6e). As described for (S)-
6c, with (R)-3e [19] (200 mg, 0.304 mmol), 3N HCl (MeCN/H2O 1:1, 3 ml), 3 h at 60°;
prep. TLC (CH2Cl2/MeOH 10:1): 113 mg (76%) of (R)-6e. Colorless solid. M.p. 144 –
145°. Rf (CH2Cl2/MeOH 10:1) 0.37. IR: 3309m, 2957s, 2871w, 1724s, 1662vs, 1526s,
1455w, 1387w, 1246w, 1049w, 737w. 1H-NMR: 7.33 (br., 5 arom. H); 7.23 (br. s, NH);
7.03 (br. s, NH); 5.52 (br., NH of Leu); 5.10 (br. s, PhCH2O); 4.2 – 4.1 (m, CH(2) of Leu);
2.5 – 2.35 (m, CH(3) of Ala(2cPent)); 1.8 – 1.3 (m, CH2(3) and CH(4) of Leu, 2 Me of
Aib, Me of Ala(2cPent), 4 CH2 of Ala(2cPent)); 0.95 – 0.9 (m, 2 Me of Leu). 
13C-NMR:
173.9, 172.8 (2s, 2 CONH, COOH); 156.7 (s, OCONH); 136.0 (s, 1 arom. C); 128.5,
128.2, 127.9 (3d, 5 arom. CH); 67.2 (t, PhCH2O); 61.9, 57.4 (2s, C(2) of Ala(2cPent), C(2)
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of Aib); 53.9 (d, C(2) of Leu); 46.2 (d, C(3) of Ala(2cPent)); 41.1 (t, C(3) of Leu); 27.0,
26.7, 25.3 (3t, 4 CH2 of cPent); 24.6 (d, C(4) of Leu); 22.8, 21.8, 19.5 (3q, 2 Me of Aib,
Me of Ala(2cPent), 2 Me of Leu). ESI-MS (MeOH, NaI): 525 (10), 513 (32), 512 (100, [M
+ Na]+), 503 (6), 491 (29), 490 (99, [M  + 1]+), 472 (47, [M  – OH]+), 333 (8, [M  –
Ala(2cPent)]+). Anal. calc. for C26H39N3O6 (489.61): C 63.78, H 8.03, N 8.58; found: C
63.50, H 8.08, N 8.53.
10.2.  Benzyl {(S)-1-[({2-[((R)-2-{[4-Amino-(S)-1-({[(S)-1-(hydroxymethyl)-2-
methylpropyl]amino}carbonyl)-4-oxobutyl]amino}-1-cyclopentyl-1-methyl-2-oxo-
ethyl)amino]-1,1-dimethyl-2-oxoethyl}amino)carbonyl]-3-methylbutyl}carbamate (Z-Leu-
Aib-(R)-Ala(2cPent)-Gln-Valol; (R)-2e). As described for 2a, with (R)-6e (220 mg, 0.449
mmol), Et3N (136 mg, 1.35 mmol), abs. DMF (3.5 ml), HATU (171 mg, 0.450 mmol), 4
min at 0°, HOAt (62 mg, 0.456 mmol), 4 min at 0°, 11 (106 mg, 0.458 mmol), 3 h at 0°
and 47 h at r.t.; CC (CH2Cl2/MeOH 10:1) and prep. TLC (CH2Cl2/MeOH 10:1): 88 mg
(28%) of (R)-2e and 78 mg of starting material (R)-6e (35%). Colorless solid. M.p. 209.5 –
210.8°. Rf (CH2Cl2/MeOH 10:1) 0.23. IR: 3426vs, 2959s, 2871m, 1661vs, 1532s, 1455w,
1386w, 1261w, 1175w, 1121w, 1048w, 741w. 1H-NMR: 8.09 (br., NH); 7.70 (br., 2 NH);
7.35 – 7.3 (m, 5 arom. H); 7.09 (br., 2 NH); 5.37 (br., 2 NH); 5.14, 5.07 (AB, J = 13.1,
PhCH2O); 4.35 – 4.0, 3.75 – 3.6 (2m, CH(2) of Gln, CH(2) of Leu, CH(2) and CH2(1) of
Valol); 2.65 – 2.45, 2.35 – 2.25 (2m, CH2(4) and CH2(3) of Gln); 1.85 – 1.25 (m, CH2(3) of
Leu, 4 CH2 of Ala(2cPent), CH(4) of Leu, CH(3) of Valol, CH(3) of Ala(2cPent)); 1.45,
1.42 (2s, 2 Me(3) of Aib); 1.28 (s, Me(3) of Ala(2cPent)); 0.95 – 0.85 (m, 2 Me(4) of
Valol, 2 Me(5) of Leu). 1H-NMR (CD3OD): 8.51 (br. S, NH); 7.74 (d, J = 7.2, NH); 7.56
(d, J = 8.9, NH); 7.4 – 7.25 (m, 5 arom. H); 7.11 (br. s, NH); 5.15–5.05 (m, PhCH2O); 4.25
– 4.1 (m, CH(2) of Gln, CH(2) of Leu); 3.7 – 3.6 (m, CH(2) and CH2(1) of Valol); 2.5 –
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2.35, 2.2 – 2.15, 1.9 – 1.85, 1.7 – 1.4 (4m, CH(3) of Valol, CH(3) of Ala(2cPent), CH2(3)
of Leu, CH2(4) and CH2(3) of Gln, 4 CH2 of Ala(2cPent), CH(4) of Leu, Me of
Ala(2cPent), 2 Me of Aib); 1.0 – 0.9 (m, 2 Me of Valol, 2 Me of Leu). 13C-NMR: 177.5,
176.0, 174.9, 174.6, 173.5 (5s, 5 CONH); 157.1 (s, OCONH); ca. 137 (s, 1 arom. C);
128.5, 127.9, 127.2 (3d, 5 arom. CH); 67.0, 61.6 (2t, PhCH2O, C(1) of Valol); 58.0, 55.3,
54.0 (3d , C(2) of Gln, C(2) of Valol, C(2) of Leu); 57.0 (s, C(2) of Aib, C(2) of
Ala(2cPent)); 44.4 (d, C(3) of Ala(2cPent)); ca. 39.5, ca. 31, ca. 27, 25.0 (4t, 4 CH2 of
Ala(2cPent), C(4) and C(3) of Gln, C(3) of Leu); 28.8, 24.7 (2d, C(3) of Valol, C(4) of
Leu); 22.6, 21.8, 20.3, 19.4, 19.0 (5q, 2 Me of Aib, Me of Ala(2cPent), 2 Me of Valol, 2
Me of Leu). 13C-NMR (CD3OD): 178.1, 176.6, 176.0, 175.8, 174.2 (5s, 5 CONH); 158.7
(s, OCONH); 138.2 (s, 1 arom. C); 129.4, 128.9, 128.5 (3d, 5 arom. CH); 67.6, 63.3 (2t,
PhCH2O, C(1) of Valol); 62.9, 57.9 (2s, C(2) of Aib, C(2) of Ala(2cPent)); 58.3, 55.3, 55.2
(3d, C(2) of Gln, C(2) of Valol, C(2) of Leu); 47.6 (d, C(3) of Ala(2cPent)); 41.6, 33.2,
28.7, 28.4, 28.2, 26.6, 26.2 (7t, 4 CH2 of Ala(2cPent), C(4) and C(3) of Gln, C(3) of Leu);
30.0, 25.8 (2d, C(3) of Valol, C(4) of Leu); 24.6, 23.2, 22.2, 20.0, 19.7, 19.1 (6q, 2 Me of
Aib, Me of Ala(2cPent), 2 Me of Valol, 2 Me of Leu). ESI-MS (CH2Cl2, MeOH): 725 (29,
[M + Na]+), 703 (100, [M + 1]+), 685 (7, [M – OH]+), 600 (28, [M – Valol]+), 472 (30, [M –
Gln-Valol]+). Anal. calc. for C36H58N6O8 (702.89): C 61.52, H 8.32, N 11.96; found: C
61.36, H 8.31, N 11.70.
Crystals suitable for an X-ray crystal-structure determination were obtained from
AcOEt/MeOH by slow evaporation of the solvent.
11. Peptides with Xaa = (S)-Leu(2Me). 11.1. (S)-2-({2-[((S)-2-{[(Benzyloxy)carbo-
nyl]amino}-4-methyl-1-oxopentyl)amino]-2-methyl-1-oxopropyl}amino)-2,4-dimethyl-
pentanoic Acid (Z-Leu-Aib-(S)-Leu(2Me)-OH; (S)-6f). As described for (S)-6c, with (S)-3f
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[19] (249 mg, 0.390 mmol), 3N HCl (MeCN/H2O 1:1, 2 ml), 4 h at 60°; prep. TLC
(CH2Cl2/MeOH 10:1): 87 mg (47%) of (S)-6f and 28%
2) of benzyl [(S)-1-({[1,1-dimethyl-
2-({(S)-1,3-dimethyl-1-[(methylamino)carbonyl]butyl}amino)-2-oxoethyl]amino}-
carbonyl)-3-methylbutyl]carbamate (Z-Leu-Aib-(S)-Leu(2Me)-NHMe; (S)-7f).
Data of (S)-6f: Colorless solid. M.p. 107 – 108°. Rf (CH2Cl2/MeOH 10:1) 0.19. IR:
3306m, 2958s, 1717s, 1659s, 1523s, 1454m, 1388m, 1367m, 1237m, 1159m, 1045m, 954w,
908w, 855w, 789w, 757w, 736w, 697m. 1H-NMR: 7.3 – 7.25 (m, 5 arom. H, NH); 7.19 (s,
NH); 5.85 (d, J = 6.9, NH); 5.1 – 5.05 (m, PhCH2O); 4.2 – 4.15 (m, CH(2) of Leu); 2.15 –
2.1 (m, CH(4) of Leu(2Me)); 1.8 – 1.5 (m, CH2(3) and CH(4) of Leu, 2 Me of Aib, CH2(3)
and Me(3) of Leu(2Me)); 0.95 – 0.85 (m, 2 Me of Leu, 2 Me(5) of Leu(2Me)). 13C-NMR:
177.5 (s, COOH); 173.4, 172.8 (2s, 2 CONH); 156.5 (s, OCONH); 136.0 (s, 1 arom. C);
128.4, 128.1, 127.8 (3d, 5 arom. CH); 67.0 (t, PhCH2O); 59.8, 57.3 (2s, C(2) of Aib, C(2)
of Leu(2Me)); 54.0 (d, C(2) of Leu); 44.5, 40.9 (2t, C(3) of Leu, C(3) of Leu(2Me)); 24.6,
24.4 (2d, C(4) of Leu(2Me), C(4) of Leu); 25.0, 23.9, 23.5, 23.1, 22.9, 21.8 (6q, 2 Me of
Aib, Me(3) and 2 Me(5) of Leu(2Me), 2 Me of Leu). ESI-MS (MeOH): 522 (27), 500
(100, [M + Na]+). Anal. calc. for C25H39N3O6 (477.60): C 62.87, H 8.23, N 8.80; found: C
62.77, H 8.14, N 8.68.
Data of (S)-7f: Colorless solid. M.p. 78.5 – 79.5°. Rf (CH2Cl2/MeOH 10:1) 0.44. IR:
3321s, 3038w, 2957s, 2871w, 1704vs, 1652vs, 1537s, 1455m, 1411w, 1382m, 1365w,
1331w, 1261s, 1223w, 1173w, 1115w, 1051w, 1031w, 907w, 789w, 726w, 693w. 1H-NMR
(CD3OD): 7.35 – 7.3 (m, 5 arom. H); 5.08 (br. s, PhCH2O); 4.06 (dd, J = 8.4, 6.5, CH(2) of
                                                 
2) The side product (S)-7f was not isolated in the described reaction. In another experiment,
it was isolated in 28% yield: starting material (S)-3f: 249 mg (0.386 mmol); side product
(S)-7f: 105 mg (0.214 mmol).
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Leu); 2.69 (s, MeN); 2.0 – 1.5 (m , CH2(3) of Leu(2Me), CH2(3) of Leu, CH(4) of
Leu(2Me), CH(4) of Leu); 1.40 (s, 2 Me of Aib); 1.38 (s, Me(3) of Leu(2Me)); 0.97, 0.95,
0.92, 0.86 (4d , J = 7.3, 7.5, 6.9, 6.6, 2 Me of Leu, 2 Me(5) of Leu(2Me)). 13C-NMR
(CD3OD): ca. 177.5, 175.9, 175.5 (3s, 3 CONH); ca. 158.5 (s, OCONH); ca. 138 (s, 1
arom. C); 129.4, 128.9, 128.5 (3d, 5 arom. CH); 67.5 (t, PhCH2O); 61.1, 58.0 (2s, C(2) of
Leu(2Me), C(2) of Aib); 55.1 (d, C(2) of Leu); 45.2, 41.4 (2t, C(3) of Leu(2Me), C(3) of
Leu); 25.8, 24.9 (2d, C(4) of Leu(2Me), C(4) of Leu); 26.5, 24.6, 24.4, 24.2, 23.2, 22.0
(6q, MeN, 2 Me of Aib, Me(3) of Leu(2Me), 2 Me(5) of Leu(2Me), 2 Me of Leu). CI-MS
(NH3): 492 (10), 491 (32, [M + 1]
+), 460 (32, [M – HNMe]+), 384 (22), 383 (32, [M –
OBn]+), 357 (9), 231 (12), 214 (7). Anal. calc. for C26H42N4O5·0.2 H2O (494.24): C 63.18,




Leu(2Me)-Gln-Valol; (S)-2f). As described for 2a, with (S)-6f (161 mg, 0.337 mmol), Et3N
(102 mg, 1.011 mmol), abs. DMF (2.5 ml), HATU (128 mg, 0.337 mmol), 4 min at r.t.,
HOBt (51 mg, 0.337 mmol), 5 min at r.t., 11 (78 mg, 0.337 mmol), 42 h at r.t.; CC
(CH2Cl2/MeOH 10:1): 139 mg (60%) of (S)-2f. Colorless solid. M.p. 154 – 155°. Rf
(CH2Cl2/MeOH 10:1) 0.17. IR: 3312m, 2956m, 1653s, 1534s, 1466m, 1386w, 1360m,
1260m, 1046w, 847w, 814w, 738w. 1H-NMR: 7.96 (br., NH); 7.81 (br., NH); 7.35 – 7.2 (m,
5 arom. H, NH); 7.04 (br., NH); 6.88 (br. s, NH); 6.71 (br., NH); 5.68 (br., NH); 5.15, 5.12
(AB, J = 12.7, PhCH2O); 4.0 – 3.8, 3.7 – 3.55 (2m, CH(2) of Gln, CH(2) of Leu, CH(2) and
CH2(1) of Valol); 2.35 – 2.15 (m, CH2(4) and CH2(3) of Gln); 1.8 – 1.6 (m, CH2(3) of
Leu(2Me), CH2(3) of Leu, CH(3) of Valol, CH(4) of Leu, CH(4) of Leu(2Me)); 1.5 – 1.25
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(m, 2 Me of Aib, Me(3) of Leu(2Me)); 0.95 – 0.8 (m, 2 Me of Valol, 2 Me(5) of Leu(2Me),
2 Me of Leu). 13C-NMR: 175.6, 175.2, 175.1, 174.8, 172.8 (5s, 5 CONH); 157.1 (s,
OCONH); 136.7 (s, 1 arom. C); 128.5, 127.9, 127.2 (3d, 5 arom. CH); 66.7, 63.5 (2t,
PhCH2O, C(1) of Valol); 59.7, 56.8 (2s, C(2) of Leu(2Me), C(2) of 2 Aib); 57.5, 55.8 (2d,
C(2) of Gln, C(2) of Valol, C(2) of Leu); 48.3, 39.8, 32.6, 27.6 (4t, C(3) of Leu, C(3) of
Leu(2Me), C(4) and C(3) of Gln); 28.9, 24.6, 23.4 (3d, C(3) of Valol, C(4) of Leu(2Me),
C(4) of Leu); 26.3, 24.3, 24.2, 23.0, 22.7, 21.6, 20.9, 19.5, 19.2 (9q, 2 Me of Aib, Me(3) of
Leu(2Me), 2 Me of Valol, 2 Me(5) of Leu(2Me), 2 Me of Leu). ESI-MS (MeOH): 714 (15,
[M + Na]+), 691 (100, [M  + 1]+). Anal. calc. for C35H58N6O8·H2O (708.90): C 59.30, H




Leu(2Me)-Gln-Valol; (S)-13f). As described for 13a, with (S)-2f (80 mg, 0.116 mmol),
Pd/C (10% on activated charcoal, 8 mg), MeOH (5 ml), and H2, 75 min at r.t., filtration
over Celite, abs. CH2Cl2 (5 ml), Et3N (25 mg, 0.248 mmol), 4-bromobenzoylchloride (31
mg, 0.139 mmol), 3 h at r.t., filtration and washing with CH2Cl2: 60 mg (70%) of (S)-13f.
Colorless solid. M.p. 246 – 247°. Rf (CH2Cl2/MeOH 10:1) 0.18. IR: 3336m, 2959m,
2477m, 1648vs, 1542s, 1364m, 1278w, 1176w, 1072w, 1011w, 850w , 761w . 1H-NMR
(CD3OD): 7.83, 7.62 (AA'BB', J = 8.5, 4 arom. H); 4.55 – 4.5, 4.1 – 4.05 (2m, CH(2) of
Gln and CH(2) of Leu); 3.65 – 3.6 (m, CH2(1) and CH(2) of Valol); 2.4 – 2.05, 1.85 – 1.65
(2m, CH2(4) of Gln and CH2(3) of Gln, CH(3) of Valol, CH(4) and CH2(3) of Leu, CH(4)
and CH2(3) of Leu(2Me)); 1.45, 1.44, 1.41 (3s, 2 Me of Aib, Me(3) of Leu(2Me)); 1.01,
0.99 (2d, J = 5.6, 5.7, 2 Me); 0.95 – 0.9 (m, 3 Me); 0.81 (d, J = 6.8, 1 Me). 13C-NMR
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(CD3OD): 177.7, 177.0, 176.7, 175.8, 174.4 (5s, 5 CONH); 169.6 (s, 1 CO (amide,
pBrBz)); 134.0 (s, 1 arom. C); 132.8, 130.7 (2d, 4 arom. CH); 127.4 (s, 1 arom. CBr); 63.6
(t, C(1) of Valol); 61.2, 58.1 (2s, C(2) of Leu(2Me), C(2) of Aib); 58.6, 56.5, 54.5 (3d,
C(2) of Gln, C(2) of Valol, C(2) of Leu); 48.5, 41.6, 33.8, 28.5 (4t, C(3) of Leu, C(3) of
Leu(2Me), C(4) of Gln, C(3) of Gln); 30.1, 26.1, 24.9 (3d, C(3) of Valol, C(4) of Leu, C(4)
of Leu(2Me)); 25.5, 25.0, 23.4, 22.7, 22.2, 20.1, 19.4 (7q, 2 Me of Aib, Me(3) of
Leu(2Me), 2 Me of Valol, 2 Me of Leu, 2 Me(5) of Leu(2Me)). ESI-MS (NaI): 763 (24, [M
+ Na]+, 81Br), 741 (100, [M + 1]+, 81Br), 638 (6, [M – Valol]+, 81Br), 510 (10, [M – Gln-
Valol]+, 81Br). Anal. calc. for C34H55BrN6O7 (739.75): C 55.20, H 7.49, N 11.36; found: C
55.10, H 7.53, N 11.11.
Crystals suitable for an X-ray crystal-structure determination were obtained from
CD3OD by slow evaporation of the solvent.
12. Peptides with Xaa = (R)-Leu(2Me). 12.1. (R)-2-({2-[((S)-2-{[(Benzyloxy)carbo-
nyl]amino}-4-methyl-1-oxopentyl)amino]-2-methyl-1-oxopropyl}amino)-2,4-dimethyl-
pentanoic Acid (Z-Leu-Aib-(R)-Leu(2Me)-OH; (R)-6f). As described for (S)-6c, with (R)-3f
[19] (200 mg, 0.31 mmol), 3N HCl (MeCN/H2O 1:1, 2 ml), 3 h at 60°; prep. TLC
(CH2Cl2/MeOH 10:1) gave 78 mg (53%) of (R)-6f and 35%
3) of benzyl [(S)-1-({[1,1-
dimethyl-2-({(R)-1,3-dimethyl-1-[(methylamino)carbonyl]butyl}amino)-2-oxoethyl]-
amino}carbonyl)-3-methylbutyl]carbamate (Z-Leu-Aib-(R)-Leu(2Me)-NHMe; (R)-7f).
Data of (R)-6f: Colorless solid. M.p. 152 – 153°. Rf (CH2Cl2/MeOH 10:1) 0.17. IR:
3301s, 2956s, 1727s, 1661s, 1542s, 1456m, 1366m, 1235m, 1162m, 1046m, 754w, 697m.
                                                 
3) The side product (R)-7f was not isolated in the described reaction. In another
experiment, it was isolated in 35% yield: starting material (R)-3f: 909 mg (1.410 mmol);
side product (R)-7f: 242 mg (0.493 mmol).
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1H-NMR: 7.35 – 7.3 (m, 5 arom. H); 7.2 – 7.05 (m, 2 NH); 5.75 (d, J = 6.4, NH); 5.11 (br.,
PhCH2O); 4.15 – 4.1 (m, CH(2) of Leu); 2.15 – 2.1 (m, CH(4) of Leu(2Me)); 1.8 – 1.45
(m, CH2(3) and CH(4) of Leu, CH2(3) and Me(3) of Leu(2Me), 2 Me of Aib); 0.95 – 0.85
(m, 2 Me of Leu, 2 Me(5) of Leu(2Me)). 13C-NMR: 177.0 (s, COOH); 173.4, 172.6 (2s, 2
CONH); 156.6 (s, OCONH); 136.0 (s, 1 arom. C); 128.5, 128.1, 127.8 (3d, 5 arom. CH);
67.1 (t, PhCH2O); 59.7, 57.2 (2s, C(2) of Leu(2Me), C(2) of Aib); 54.1 (d, C(2) of Leu);
44.7, 40.9 (2t, C(3) of Leu, C(3) of Leu(2Me)); 24.6, 24.3 (2d, C(4) of Leu(2Me), C(4) of
Leu); 25.3, 24.9, 24.5, 23.8, 23.2, 22.8, 21.8 (7q, 2 Me of Aib, Me(3) and 2 Me(5) of
Leu(2Me), 2 Me of Leu). ESI-MS (MeOH): 495 (14), 479 (30), 478 (100, [M + 1]+), 460
(15, [M – OH]+), 333 (12, [M – Leu(2Me)]+). Anal. calc. for C25H39N3O6·0.5 H2O (486.61):
C 61.71, H 8.29, N 8.64; found: C 61.77, H 8.08, N 8.30.
Data of (R)-7f: Colorless solid. M.p. 110 – 111°. Rf (CH2Cl2/MeOH 10:1) 0.45. IR:
3293s, 2958m, 2873w, 1706s, 1654vs, 1518vs, 1464m, 1411w, 1386w, 1369w, 1270s,
1242m, 1175w , 1119w , 1049m , 1029w , 970w , 789w , 745w , 698w , 658w . 1H-NMR
(CD3OD): 7.35 – 7.25 (m, 5 arom. H); 5.09 (br. s, PhCH2O); 4.06 (dd, J = 8.9, 6.1, CH(2)
of Leu); 2.69 (s, MeN); 1.8 – 1.65, 1.65 – 1.45 (2m, CH2(3) of Leu(2Me), CH2(3) of Leu,
CH(4) of Leu(2Me), CH(4) of Leu); 1.47 (s, Me(3) of Leu(2Me)); 1.41, 1.39 (2s, 2 Me of
Aib); 0.97, 0.95, 0.91, 0.89 (4d, J = 7.6, 6.9, 6.9, 6.5, 2 Me of Leu, 2 Me(5) of Leu(2Me)).
13C-NMR (CD3OD): ca. 177.5, ca. 176, ca. 175 (3s, 3 CONH); ca. 158 (s, OCONH); ca.
138 (s, 1 arom. C); 129.4, 128.9, 128.5 (3d, 5 arom. CH); 67.5 (t, PhCH2O); 61.2, 58.0 (2s,
C(2) of Leu(2Me), C(2) of Aib); 55.2 (d, C(2) of Leu); 47.3, 41.4 (2t, C(3) of Leu(2Me),
C(3) of Leu); 25.7, 25.0 (2d, C(4) of Leu(2Me), C(4) of Leu); 26.5, 26.0, 24.3, 24.1, 23.2,
22.5, 22.0 (7q, MeN, 2 Me of Aib, Me(3) of Leu(2Me), 2 Me(5) of Leu(2Me), 2 Me of
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Leu). CI-MS (NH3): 491 (4, [M + 1]
+), 384 (21), 383 (32, [M – OBn]+), 231 (7). Anal. calc.




Leu(2Me)-Gln-Valol; (R)-2f). As described for 2a, with (R)-6f (240 mg, 0.503 mmol),
Et3N (153 mg, 1.515 mmol), abs. DMF (5 ml), HATU (191 mg, 0.502 mmol), 4 min at r.t.,
HOBt (76 mg, 0.502 mmol), 5 min at r.t., 11 (117 mg, 0.506 mmol), 94 h at r.t.; prep. TLC
(CH2Cl2/MeOH 10:1): 177 mg (53%) of (R)-2f. Colorless foam. M.p. 105 – 107°. R f
(CH2Cl2/MeOH 10:1) 0.14. IR: 3302s, 2958m, 2871m, 1659s, 1533s, 1455m, 1386m,
1356m, 1264m, 1171m, 1122w, 1055w, 852w, 786w, 740m, 697m. 1H-NMR: 7.93 (br.,
NH); 7.84 (d, J = 5.1, NH); 7.4 – 7.25 (m, 5 arom. H); 7.2 – 7.15 (m, NH); 7.11 (br. s,
NH); 7.02 (br., NH); 6.70 (br., NH); 5.70 (br., NH); 5.25 – 5.05 (m, PhCH2O); 4.1 – 3.55
(m, CH(2) of Gln, CH(2) of Leu, CH(2) and CH2(1) of Valol); 2.45 – 2.0 (m, CH2(4) and
CH2(3) of Gln, CH(3) of Valol); 1.8 – 1.65 (m, CH2(3) of Leu(2Me), CH2(3) of Leu); 1.55
– 1.25 (m, 2 Me of Aib, Me(3) of Leu(2Me)); 0.95 – 0.8 (m, 2 Me of Valol, CH(4) of Leu,
CH(4) of Leu(2Me), 2 Me(5) of Leu(2Me), 2 Me of Leu). 13C-NMR: 176.9, 175.1, 175.1,
174.6, 173.0 (5s, 5 CONH); 157.4 (s, OCONH); 136.6 (s, 1 arom. C); 128.5, 128.0, 126.9
(3d, 5 arom. CH); 66.6, 63.5 (2t, PhCH2O, C(1) of Valol); 59.8, 56.9 (2s, C(2) of
Leu(2Me), C(2) of 2 Aib); 57.5, 56.1, 55.5 (3d, C(2) of Gln, C(2) of Valol, C(2) of Leu);
40.6, 39.7, 32.6, 27.6 (4t, C(3) of Leu, C(3) of Leu(2Me), C(4) and C(3) of Gln); 28.9 (d,
C(3) of Valol); 24.6, 23.4 (2d, C(4) of Leu(2Me), C(4) of Leu); 26.4, 25.0, 24.5, 24.2,
23.0, 22.7, 21.6, 19.5, 19.2 (9q, 2 Me of Aib, Me(3) of Leu(2Me), 2 Me of Valol, 2 Me(5)
of Leu(2Me), 2 Me of Leu). ESI-MS (MeOH): 729 (10, [M + K]+), 714 (22, [M + Na]+),
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691 (100, [M + 1]+), 674 (7, [M – OH]+), 588 (17, [M – Valol]+), 460 (18, [M – Gln-
Valol]+). Anal. calc. for C35H58N6O8·H2O (708.90): C 59.30, H 8.53, N 11.86; found: C




Leu(2Me)-Gln-Valol; (R)-13f). As described for 13a, with (R)-2f (50 mg, 0.072 mmol),
Pd/C (10% on activated charcoal, 7 mg), MeOH (4 ml), and H2, 70 min at r.t., filtration
over Celite, abs. CH2Cl2 (4 ml), Et3N (16 mg, 0.158 mmol), 4-bromobenzoylchloride (18.5
mg, 0.084 mmol), 2 h at r.t., evaporation and prep. TLC (CH2Cl2/MeOH 10:1): 16 mg
(30%) of (R)-13f. M.p. 124 – 125°. Rf (CH2Cl2/MeOH 10:1) 0.14. IR: 3317s, 3064w,
2959m, 1651vs, 1592m, 1483m, 1448m, 1428m, 1382m, 1335m, 1276m, 1234m, 1160w,
1140m, 1073w, 1012w, 974w, 961w, 846w, 806w, 784w, 722w, 696m. 1H-NMR (CD3OD):
7.95 – 7.9 (m, NH); 7.84, 7.62 (AA'BB', J = 8.5, 8.6, 4 arom. H); 7.45 (br. s, NH); 7.4 –
7.35 (m, NH); 4.6 – 4.5, 4.2 – 4.1 (2m, CH(2) of Gln, CH(2) of Leu); 3.65 – 3.6 (m, CH2(1)
and CH(2) of Valol); 2.4 – 1.6, 1.3 – 1.25 (2m, CH2(4) and CH2(3) of Gln, CH(3) of Valol,
CH(4) and CH2(3) of Leu, CH(4) and CH2(3) of Leu(2Me)); 1.45 (s, 2 Me of Aib); 1.43 (s,
Me(3) of Leu(2Me)); 1.01, 0.99 (2d, J = 5.8, 5.7, 2 Me of Valol); 0.88, 0.86, 0.83, 0.81
(4d, J = 6.9, 6.6, 5.7, 6.0, 2 Me(5) of Leu(2Me), 2 Me of Leu). 13C-NMR (CD3OD): ca.
178, 177.5, 176.3, 175.5, 174.2, ca. 171 (6s, 6 CONH); ca. 134 (s, 1 arom. C); 132.7, 130.6
(2d, 4 arom. CH); ca. 127 (s, 1 arom. CBr); 63.4 (t, C(1) of Valol); 61.3, 58.0 (2s, C(2) of
Leu(2Me), C(2) of Aib); 58.4, 55.7, 54.3 (3d, C(2) of Gln, C(2) of Valol, C(2) of Leu);
45.0, 41.2, 33.4, 28.8 (4t, C(3) of Leu, C(3) of Leu(2Me), C(4) of Gln, C(3) of Gln); 29.9,
26.0, 24.7 (3d, C(3) of Valol, C(4) of Leu, C(4) of Leu(2Me)); 25.2, 25.2, 25.1, 24.9, 23.8,
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23.3, 22.1, 19.9, 19.2 (9q, 2 Me of Aib, Me(3) of Leu(2Me), 2 Me of Valol, 2 Me of Leu, 2
Me(5) of Leu(2Me)). ESI-MS (NaI): 765 (12), 764 (45), 763 (100, [M + Na]+, 81Br), 762
(41), 741 (74, [M + Na]+, 79Br). Anal. calc. for C34H55BrN6O7·0.5 H2O (748.76): C 54.54,
H 7.54, N 11.22; found: C 54.29, H 7.55, N 10.21.
13. Peptides with Xaa = (S)-Phe(2Me). 13.1. Benzyl [(S)-1-({[2-({(S)-1-Benzyl-2-
[(S)-2-(1-methoxy-1-methylethyl)pyrrolidin-1-yl]-1-methyl-2-oxoethyl}amino)-1,1-di-
methyl-2-oxoethyl]amino}carbonyl)-3-methylbutyl]carbamate (Z-Leu-Aib-(S)-Phe(2Me)-
NCp{2-[(1-Me)(1-MeO)Et]}; (S)-3h). As described for 3a, with 5 [19] (109 mg, 0.311
mmol), 1-((S)-2-benzyl-2-methyl-2H-azirin-3-yl)-2-((S)-1-methoxy-1-methylethyl)pyrrol-
idine ((S)-1h [17], 95 mg, 0.332 mmol), abs. CH2Cl2 (3 ml), 17 h at r.t., 2N HCl, 1N NaOH,
sat. NaCl-soln.; CC (CH2Cl2/MeOH 100:4): 140 mg (70%) of (S)-3h. M.p. 79 – 80°. Rf
(CH2Cl2/MeOH 20:1) 0.30. IR: 3330s, 2957s, 1666vs, 1623vs, 1498s, 1454s, 1413m,
1384m, 1317m, 1243m, 1086m, 1061m, 922w, 739w, 701m. 1H-NMR (CD3OD): 7.3 – 7.1
(m, 10 arom. H); 5.12, 5.04 (AB, J = 12.7, PhCH2O); 4.46 (dd, J = 8.5, 3.3, CHN of Cp);
4.04 (t, J = 7.5, CH(2) of Leu); 3.89 (td, J = 8.4, 2.5, CHN of Cp); 3.65 – 3.3 (m, CHN of
Cp); 3.19, 3.07 (AB, J = 13.9, CH2(3) of Phe(2Me)); 3.15 (s, MeO); 2.0 – 1.9 (m, CH(4) of
Leu); 1.8 – 1.6 (m , 4 CH of Cp); 1.55 – 1.5 (m , CH2(3) of Leu); 1.49 (s, Me(3) of
Phe(2Me)); 1.44, 1.43 (2s, 2 Me of Aib); 1.16, 1.08 (2s, Me2(MeO)C); 0.97, 0.94 (2d, J =
7.3, 7.1, 2 Me of Leu). 13C-NMR (CD3OD): 175.3, 172.6 (2s, 3 CONH); ca. 158 (s,
OCONH); 138.2, 137.4 (2s, 2 arom. C); 131.7, 129.4, 129.1, 128.9, 128.3, 127.9 (6d, 10
arom. CH); 80.0 (s, Me2(OMe)C); 67.3 (t, PhCH2O); 65.8, 55.3 (2d, C(2) of Leu, CHN of
Cp); 62.2 (s, C(2) of Phe(2Me)); 58.4 (s, C(2) of Aib); 49.5 (q, MeO); 48.9, 44.1, 41.5,
26.0, 24.5 (5t, 3 CH2 of Cp, C(3) of Leu, C(3) of Phe(2Me)); 26.9, 24.6, 24.0, 23.5, 23.2,
22.2 (6q, Me2C, 2 Me of Aib, Me(3) of Phe(2Me), 2 Me of Leu); 25.8 (d, C(4) of Leu).
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ESI-MS (MeOH, CH2Cl2, NaI): 659 (100, [M + Na]
+). Anal. calc. for C36H52N4O6·0.25
H2O (641.34): C 67.42, H 8.25, N 8.74; found: C 67.41, H 8.08, N 8.38.
13 .2 .  ( S)-2-Benzyl-2-({2-[((S)-2-{[(benzyloxy)carbonyl]amino}-4-methyl-1-oxo-
pentyl)amino]-2-methyl-1-oxopropyl}amino)propanoic Acid (Z-Leu-Aib-(S)-Phe(2Me)-
OH; (S)-6g). 13.2.1. Hydrolysis of (S)-3h. As described for (S)-6c, with (S)-3h (140 mg,
0.219 mmol), 3N HCl (THF/H2O 1:1, 8 ml), 23 h at 40°; CC (CH2Cl2/MeOH 100:9): 90
mg (80%) of (S)-6g.
13.2.2. Hydrolysis of (S)-3g. As described for (S)-6c, with (S)-3g [19] (200 mg, 0.295
mmol), 3N HCl (MeCN/H2O 1:1, 6 ml), 3 h at 60°; CC (CH2Cl2/MeOH 100:2) and prep.
TLC (CH2Cl2/MeOH 10:1): 37 mg (25%) of (S)-6g. Colorless solid. M.p. 130.2 – 130.6°.
Rf (CH2Cl2/MeOH 20:1) 0.30. IR: 3330s, 3060m, 3030m, 2960m, 2870w, 1660vs, 1605s,
1515s, 1500s, 1455s, 1405m, 1365m, 1265m, 1245m, 1210m, 1170w, 1120w, 1045w,
1030w, 1000w, 960w, 910w, 780w, 740w, 700m. 1H-NMR (CD3OD): 7.45 (br. s, NH); 7.3
– 7.25, 7.2 – 7.1 (2m, 10 arom. H); 5.1 – 5.05 (m, PhCH2O); 4.15 (t, J = 7.4, CH(2) of
Leu); 3.37, 3.31 (AB, J = 13.3, CH2(3) of Phe(2Me)); 1.7 – 1.6 (m, CH(4) of Leu); 1.6 –
1.55 (m, CH2(3) of Leu); 1.51 (s, Me(3) of Phe(2Me)); 1.38, 1.33 (2s, 2 Me of Aib); 0.93,
0.91 (2d, J = 6.8, 2 Me of Leu). 13C-NMR (CD3OD): 180.5 (s, COOH); 175.2, 174.8 (2s, 2
CONH); 158.5 (s, OCONH); 139.2, 138.0 (2s, 2 arom. C); 131.4, 129.5, 129.0, 128.8,
127.3 (5d, 10 arom. CH); 67.9 (t, PhCH2O); 62.8 (s, C(2) of Phe(2Me)); 58.2 (s, C(2) of
Aib); 55.1 (d, C(2) of Leu); 42.3, 41.8 (2t, C(3) of Phe(2Me), C(3) of Leu); 25.9 (d, C(4)
of Leu); 25.8, 25.1, 24.2, 23.5, 22.0 (5q, 2 Me of Aib, Me(3) of Phe(2Me), 2 Me of Leu).
ESI-MS (NaI): 556 (12), 550 (33, [M + K]+), 534 (100, [M + Na]+), 473 (8), 466 (6, [M –
COOH]+). Anal. calc. for C28H37N3O6·0.25 H2O (516.12): C 65.16, H 7.32, N 8.14; found:





Gln-Valol; (S)-2g). As described for 2b, with (S)-6g (83 mg, 0.162 mmol), Et3N (33 mg,
0.327 mmol), abs. DMF (1 ml), 5 min at 0°, HATU (64 mg, 0.168 mmol), 6 min at 0°, 11
(38 mg, 0.164 mmol), 30 min at 0°, 44 h at r.t.; CC (CH2Cl2/MeOH 10:1): 57 mg (49%) of
(S)-2g. Colorless solid. M.p. 102 – 103°. Rf (CH2Cl2/MeOH 10:1) 0.27. IR: 3300s, 3060w,
3030w, 2960m, 2870w, 1660vs, 1530s, 1455m, 1405w, 1385w, 1370w, 1340w, 1315w,
1260m, 1170w , 1120w , 1045w , 1030w , 960w , 920w , 845w , 740w , 700m . 1H-NMR
(CD3OD): 7.42 (d, J = 8.8, NH); 7.35 – 7.2, 7.15 – 7.1 (2m, 10 arom. H); 5.08, 5.05 (AB, J
= 12.7, PhCH2O); 4.15 – 4.05 (m, CH(2) of Gln, CH(2) of Leu); 3.7 – 3.65 (m, CH2(1) of
Valol); 3.65 – 3.6 (m, CH(2) of Valol); 3.22, 3.06 (AB, J = 13.6, CH2(3) of Phe(2Me)); 2.3
– 2.25 (m, CH2(4) of Gln); 2.25 – 2.2 (m, CH2(3) of Gln); 2.2 – 2.05 (m, CH(3) of Valol);
1.9 – 1.6 (m, CH(4) of Leu); 1.6 – 1.5 (m, CH2(3) of Leu); 1.43 (s, Me(3) of Phe(2Me));
1.37 (s, 2 Me of Aib); 0.95 – 0.9 (m, 2 Me of Leu, 2 Me of Valol). 13C-NMR (CD3OD):
178.0, 176.6, 176.3, 175.9, 174.3 (5s, 5 CONH); the signal for OCONH could not be
detected; 138.2, 137.3 (2s, 2 arom. C); 131.7, 129.5, 129.4, 129.1, 128.7, 128.2 (6d, 10
arom. CH); 67.8 (t, PhCH2O); 63.4 (t, C(1) of Valol); 60.7 (s, C(2) of Phe(2Me)); 58.4 (d,
C(2) of Gln); 58.0 (s, C(2) of Aib); 55.9, 55.3 (2d, C(2) of Leu, C(2) of Valol); 43.4, 41.5
(2t, C(3) of Phe(2Me), C(3) of Leu); 33.5 (t, C(4) of Gln); 30.0 (d, C(3) of Valol); 28.4 (t,
C(3) of Gln); 25.9 (d, C(4) of Leu); 25.6, 25.1, 23.5, 23.4, 22.2 (5q, 2 Me of Aib, Me(3) of
Phe(2Me), 2 Me of Leu); 20.1, 19.2 (2q, 2 Me of Valol). 1H-NMR (600 MHz): 7.68 (d, J =
4.9, NH of Gln); 7.48 (s, NH of Aib); 7.35 – 7.3, 7.25 – 7.2, 7.1 – 7.05 (3m, 10 arom. H, 1
NH); 6.92 (s, NH); 6.60 (s, 1H, NH2 of Gln); 6.51 (d, J = 4.0, NH of Leu); 5.53 (s, 1H,
46
NH2 of Gln); 5.11, 5.08 (AB, J = 12.6, PhCH2O); 4.1 – 4.05 (m, CH(2) of Gln); 4.0 – 3.95
(m, CH(2) of Leu); 3.75 – 3.7 (m, CH(2) of Valol); 3.65 – 3.6 (m, CH2(1) of Valol); 2.97,
2.94 (AB, J = 13.6, CH2(3) of Phe(2Me)); 2.3 – 2.25 (m, CH2(4) of Gln); 2.2 – 2.05 (m,
CH2(3) of Gln); 1.8 – 1.75 (m, CH(3) of Valol); 1.7 – 1.65 (m, CH(4) of Leu); 1.65 – 1.6
(m, 1H of CH2(3) of Leu); 1.5 – 1.45 (m, 1H of CH2(3) of Leu); 1.4 – 1.35 (m, 2 Me of
Aib, Me(3) of Phe(2Me)); 0.93, 0.92 (2d, J = 6.8, 8.3, 2 Me of Leu); 0.87, 0.86 (2d, J =
6.9, 2 Me of Valol). 13C-NMR (150.9 MHz): 175.1, 174.7, 174.4, 172.6 (4s, 5 CONH);
157.1 (s, OCONH); 136.4 (s, 1 arom. C of PhCH2O); 135.1 (s, 1 arom. C of Phe(2Me));
130.2, 128.6, 128.3, 128.2, 127.6, 127.3 (6d, 10 arom. CH); 67.1 (t, PhCH2O); 63.4 (t, C(1)
of Valol); 60.5 (s, C(2) of Phe(2Me)); 57.1 (s, C(2) of Aib); 57.6 (d, C(2) of Valol); 55.2,
55.1 (2d, C(2) of Leu, C(2) of Gln); 44.6 (t, C(3) of Phe(2Me)); 39.8 (t, C(3) of Leu); 32.5
(t, C(4) of Gln); 29.0 (d, C(3) of Valol); 27.3 (t, C(3) of Gln); 26.0, 23.7 (2q, 2 Me of Aib);
24.7 (d, C(4) of Leu); 22.9, 21.7 (2q, 2 Me of Leu); 21.5 (q, Me(3) of Phe(2Me)); 19.6,
19.2 (2q, 2 Me of Valol). ESI-MS (TFA): 748 (22, [M + Na]+), 726 (100, [M + 1]+), 706
(15, [M  – OH]+), 624 (68, [M – Valol]+), 494 (30, [M  – Gln-Valol]+). Anal. calc. for




(S)-Phe(2Me)-Gln-Valol; (S)-13g). As described for 13a, with (S)-2g (32 mg, 0.044
mmol), Pd/C (10% on activated charcoal, 7 mg), MeOH (2 ml), and H2, 30 min at r.t.,
filtration over Celite, CH2Cl2 (3 ml), Et3N (10 mg, 0.099 mmol), 4-bromobenzoylchloride
(10 mg, 0.046 mmol), 20 h at r.t., the precipitate was filtered and dried: 25 mg (73%) of
(S)-13g. Colorless solid. M.p. 236.7 – 237.6°. Rf (CH2Cl2/MeOH 10:1) 0.31. IR: 3417s,
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2959m, 1682vs, 1654vs, 1608m, 1540m, 1399w, 1364w, 1230m, 1184w, 1068w, 1021w,
810w. 1H-NMR (CD3OD): 7.77, 7.60 (AA'BB', J = 8.6, 4 arom. H); 7.3 – 7.25, 7.15 – 7.1
(2m, 5 arom. H); 4.5 – 4.45, 4.15 – 4.1 (2m, CH(2) of Gln and CH(2) of Leu); 3.65 – 3.55
(m, CH2(1) and CH(2) of Valol); 3.35, 3.05 (AB, J = 13.6, CH2(3) of Phe(2Me)); 2.3 –
1.95, 1.85 – 1.65 (2m, CH2(4) of Gln and CH2(3) of Gln, CH(3) of Valol, CH2(3) of Leu);
1.6 – 1.5 (m, CH(4) of Leu); 1.46, 1.40, 1.30 (3s, 2 Me of Aib, Me(3) of Phe(2Me)); 1.01,
0.98 (2d, J = 6.2, 6.3, 2 Me of Valol); 0.85,0.78 (2d, J = 6.8, 2 Me of Leu). 13C-NMR
(CD3OD): 177.9, 176.5, 175.5, 174.0 (4s, 5 CONH); 169.5 (s, 1 CO (amide, pBrBz));
137.3, 133.9 (2s, 2 arom. C); 132.7, 131.7, 130.6, 129.2, 128.0 (5d, 9 arom. CH); 127.3 (s,
1 arom. CBr); 63.2 (t, C(1) of Valol); 61.5, 58.0 (2s, C(2) of Phe(2Me), C(2) of Aib); 58.0,
55.4, 54.2 (3d, C(2) of Gln, C(2) of Valol, C(2) of Leu); ca. 48, 41.1, 33.3, 28.1 (4t, C(3)
of Leu, C(3) of Phe(2Me), C(4) of Gln, C(3) of Gln); 29.9, 26.0 (2d, C(3) of Valol, C(4) of
Leu); 24.7, 23.9, 23.3, 22.1, 19.9, 19.0 (6q, 2 Me of Aib, Me(3) of Phe(2Me), 2 Me of
Valol, 2 Me of Leu). ESI-MS (TFA): 813 (8, [M + K]+, 81Br), 798 (100, [M + Na]+, 81Br),
775 (86, [M + 1]+, 81Br), 757 (16, [M – OH]+, 81Br), 672 (25, [M – Valol]+, 81Br), 656 (12),
544 (53, [M – Gln-Valol]+, 81Br). Anal. calc. for C37H53BrN6O7·2 MeOH (837.85): C
55.91, H 7.33, N 10.03; found: C 56.23, H 7.01, N 10.57.
Recrystallization from AcOEt/MeOH/petroleum ether gave crystals suitable for an
X-ray crystal structure determination.
14. Peptides with (R)-Phe(2Me). 14.1. Benzyl [(S)-1-({[2-({(R)-1-Benzyl-2-[(S)-2-(1-
methoxy-1-methylethyl)pyrrolidin-1-yl]-1-methyl-2-oxoethyl}amino)-1,1-dimethyl-2-
oxoethyl]amino}carbonyl)-3-methylbutyl]carbamate (Z-Leu-Aib-(R)-Phe(2Me)-NCp{2-
[(1-Me)(1-MeO)Et]}; (R)-3h). As described for 3a, with 5 [19] (159 mg, 0.45 mmol), abs.
CH2Cl2 (4 ml), and (R)-1h [17] (130 mg, 0.45 mmol), abs. CH2Cl2 (5 ml), 18 h at r.t.; CC
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(CH2Cl2/MeOH 20:1, 25:1, 50:1); prep. TLC (CH2Cl2/MeOH 20:1): 229 mg (79%) of (R)-
3h. Colorless foam. M.p. 79 – 80°. Rf (CH2Cl2/MeOH 10:1) 0.57. Rf (CH2Cl2/MeOH 20:1)
0.36. IR: 3323s, 3032m, 2958s, 1665vs, 1624vs, 1527vs, 1455s, 1411s, 1384s, 1316m,
1243s, 1120m, 1086s, 1061m, 921w, 737m, 700s. 1H-NMR: 7.48 (br. s, NH); 7.4 – 7.3, 7.2
– 7.0 (2m, 10 arom. H); 6.63 (br. s, NH); 5.14 (d, NH of Leu); 5.15 – 5.1 (m, NH); 5.05,
4.99 (AB, J = 12.3, PhCH2O); 4.55 – 4.5 (m, CHN of Cp); 4.1 – 3.95 (m, CH(2) of Leu,
CHN of Cp); 3.6 – 3.4 (m, CHN of Cp, CH2(3) of Phe(2Me)); 3.16 (s, MeO); 2.05 – 1.95
(m, CH2(3) of Leu); 1.8 – 1.4 (m, 2 CH2 of Cp, 2 Me of Aib, Me(3) of Phe(2Me), CH(4) of
Leu); 1.17, 1.13 (2s, Me2C); 0.92 (d, J = 6.3, 2 Me of Leu). 
13C-NMR: 172.2, 171.5 (2s, 3
CONH); the signal for OCONH could not be detected; 136.7, 136.0 (2s, 2 arom. C); 130.9,
128.4, 128.1, 127.9, 127.9, 126.6 (6d, 10 arom. CH); 67.1 (t, PhCH2O); 64.8 (d, C(2) of
Leu); 60.8, 57.7 (2s, C(2) of Phe(2Me), C(2) of Aib); 54.2 (d, CHN of Cp); 49.1 (q, MeO);
48.1 (t, CH2N of Cp); 41.2, 40.3, 23.6 (3t, C(3) of Leu, C(3) of Phe(2Me), 2 CH2 of Cp);
25.3 (q, Me2C); 24.6 (d, C(4) of Leu); 22.9, 22.9, 22.2, 21.7 (4q, 2 Me of Aib, Me(3) of
Phe(2Me), 2 Me of Leu). ESI-MS (MeOH, AcOH): 659 (7, [M + Na]+), 639 (10), 638 (39),
637 (100, [M + 1]+). Anal. calc. for C36H52N4O6 (636.84): C 67.90, H 8.23, N 8.80; found:
C 67.73, H 8.20, N 8.61.
14.2. (S)-2-Benzyl-2-({2-[((S)-2-{[(benzyloxy)carbonyl]amino}-4-methyl-1-oxopen-
tyl)amino]-2-methyl-1-oxopropyl}amino)propanoic Acid (Z-Leu-Aib-(R)-Phe(2Me)-OH;
(R)-6g). 14.2.1. Hydrolysis of (R)-3h. As described for (S)-6c, with (R)-3h (120 mg, 0.188
mmol), 3N HCl (THF/H2O 1:1, 8 ml), 26 h at 40°; CC (CH2Cl2/MeOH 10:1): 57 mg (59%)
of (R)-6g.
14.2.2. Hydrolysis of (R)-3g. As described for (S)-6c, with (R)-3g [19] (204 mg,
0.300 mmol), 3N HCl (MeCN/H2O 1:1, 6 ml), 3 h at 60°; CC (CH2Cl2/MeOH 100:2); prep.
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TLC (CH2Cl2/MeOH 10:1): 55 mg (36%) of (R)-6g. Colorless solid. M.p. 126.8 – 127.3°.
Rf (CH2Cl2/MeOH 20:1) 0.28. IR: 3330m, 3060w, 3030w, 2960m, 2860w, 1660vs, 1530 –
1510s, 1450s, 1410m, 1390m, 1365m, 1255m, 1215m, 1170w, 1120w, 1045w, 1030w,
1000w, 960w, 910w, 780w, 740w, 700m. 1H-NMR (CD3OD): 7.3 – 7.25, 7.15 – 7.1 (2m,
10 arom. H); 5.02, 4.97 (AB, J = 12.5, PhCH2O); 4.13 (t, J = 6.4, CH(2) of Leu); 3.37, 3.31
(AB, J = 13.3, CH2(3) of Phe(2Me)); 1.7 – 1.55 (m, CH(4) of Leu); 1.55 – 1.45 (m, Me(3)
of Phe(2Me), CH2(3) of Leu); 1.41, 1.38 (2s, 2 Me of Aib); 0.92, 0.90 (2d, J = 6.8, 2 Me of
Leu). 13C-NMR (CD3OD): 180.5 (s, COOH); 175.3, 174.9 (2s, 2 CONH); 158.6 (s,
OCONH); 139.2, 138.0 (2s, 2 arom. C); 131.5, 129.5, 129.1, 128.9, 127.3 (5d, 10 arom.
CH); 66.4 (t, PhCH2O); 62.8 (s, C(2) of Phe(2Me)); 58.3 (s, C(2) of Aib); 55.3 (d, C(2) of
Leu); 42.3, 41.8 (2t, C(3) of Phe(2Me), C(3) of Leu); 25.9 (d, C(4) of Leu); 26.1, 24.9,
24.2, 23.5, 22.0 (5q, 2 Me of Aib, Me(3) of Phe(2Me), 2 Me of Leu). ESI-MS (NaI): 624
(18), 550 (20, [M + K]+), 534 (100, [M  + Na]+). Anal. calc. for C28H37N3O6·0.25 H2O




Phe(2Me)-Gln-Valol; (R)-2g). As described for 2b, with (R)-6g (53 mg, 0.104 mmol), Et3N
(22 mg, 0.218 mmol), abs. DMF (1 ml), 5 min at 0°, HATU (40 mg, 0.105 mmol), 6 min at
0°, 11 (24 mg, 0.104 mmol), 40 min at 0° and 25 h at r.t. Reaction control with TLC
showed still a considerable amount of (R)-6g. At 0°, additional HATU (8 mg, 0.021 mmol)
was added, stirred for 4 min, and 11 (6 mg, 0.026 mmol) was added. After a further 7 min
of stirring, the mixture was warmed to r.t. and stirred for 68 h. The solvent was evaporated,
the residue was dissolved in AcOEt and a small amount of MeOH, washed twice with 2N
50
HCl, once with 1N NaOH-soln. and sat. NaCl-soln., dried (MgSO4), and evaporated. A
residue, which was not soluble in 50 ml of MeOH (HATU), was filtered off. CC
(CH2Cl2/MeOH 10:1): 42 mg (56%) of (R)-2g. M.p. 94.3 – 95.0°. Rf (CH2Cl2/MeOH 10:1)
0.35. 1H-NMR (CD3OD): 8.10 (d, J = 6.8, NH); 7.40 (d, J = 8.2, NH); 7.3 – 7.1 (m, 10
arom. H); 5.03, 4.96 (AB, J = 12.5, PhCH2O); 4.2 – 4.15 (m, CH(2) of Gln); 4.01 (t, J =
7.5, CH(2) of Leu); 3.7 – 3.65 (m, CH2(1) and CH(2) of Valol); 3.53, 3.09 (2d, J = 13.7,
CH2(3) of Phe(2Me)); 2.4 – 2.35 (m, CH2(4) of Gln); 2.25 – 2.1 (m, CH2(3) of Gln); 2.0 –
1.9 (m, CH(3) of Valol); 1.7 – 1.65 (m, CH(4) of Leu); 1.52 (t, J = 7.2, CH2(3) of Leu);
1.42 (s, Me(3) of Phe(2Me)); 1.34, 1.32 (2s, 2 Me of Aib); 1.0 – 0.9 (m, 2 Me of Leu, 2 Me
of Valol). 13C-NMR (CD3OD): 177.6, 176.9, 176.2, 174.7 (4s, 5 CONH); the signal for
OCONH could not be detected; 138.2, 137.8 (2s, 2 arom. C); 132.3, 129.5, 129.1, 128.6,
127.9 (5d, 10 arom. CH); 67.7 (t, PhCH2O); 63.7 (t, C(1) of Valol); 61.3 (s, C(2) of
Phe(2Me)); 58.8 (d, C(2) of Gln); 58.0 (s, C(2) of Aib); 56.5, 56.1 (2d, C(2) of Leu, C(2)
of Valol); 41.3, 40.4 (2t, C(3) of Phe(2Me), C(3) of Leu); 33.6 (t, C(4) of Gln); 30.1 (d,
C(3) of Valol); 28.6 (t, C(3) of Gln); 25.8 (d, C(4) of Leu); 26.8, 24.7, 24.3, 23.2, 22.2 (5q,
2 Me of Aib, Me(3) of Phe(2Me), 2 Me of Leu); 20.1, 19.5 (2q, 2 Me of Valol). ESI-MS
(TFA): 748 (18, [M + Na]+), 726 (77, [M + 1]+), 708 (12, [M – OH]+), 624 (100, [M –




(R)-Phe(2Me)-Gln-Valol; (R)-13g). As described for 13a, with (R)-2g (25 mg, 0.035
mmol), Pd/C (10% on activated charcoal, 5 mg), MeOH (1.5 ml), and H2, 16 h at r.t.,
filtration over Celite, CH2Cl2 (2 ml), Et3N (10 mg, 0.099 mmol), 4-bromobenzoylchloride
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(10 mg, 0.046 mmol), 3 h at r.t., filtration and washing with CH2Cl2: 20 mg (75%) of (R)-
13g. Colorless solid. M.p. 127.4 – 128.5°. Rf (CH2Cl2/MeOH 10:1) 0.37. IR: 3422vs,
2929m, 1648s, 1534m, 1458w, 1388w, 1284w, 1070w, 1011w, 760w, 711w. ESI-MS (NaI):
806 (12), 798 (87, [M + Na]+, 81Br), 757 (8, [M – OH]+, 81Br), 729 (16), 655 (9), 613 (13),
589 (32), 573 (8), 514 (15), 485 (17), 441 (12).
After recrystallization from MeOH and acetone, crystals were obtained. The
attempted X-ray crystal-structure determination failed, as the reflexes were not strong
enough to solve the structure properly.
15. X-Ray Crystal-Structure Determination of 13a, 13b, (S)-2d, (S)-2e, (S)-13f, (S)-
13g, (R)-6c, (R)-7c, and (R)-7d (see Tables 6 and 7, and Figs. 1 and 2)4). All measurements
were conducted at low temp. using graphite-monochromated MoKα radiation (λ 0.71073
Å). The data collection and refinement parameters are given in Tables 6 and 7 ,
respectively, and views of the molecules are shown in Figs. 1 and 2. The intensities were
corrected for Lorentz and polarization effects, and for 13a, 13b, and (S)-13g, an empirical
absorption correction, based on azimuthal scans of several reflections, was also applied
[40]. For (S)-13f, a numerical absorption correction [41] was applied. Equivalent
reflections, including Friedel pairs for (S)-2e, (R)-6c, and (R)-7d, were merged. Structures
13a, 13b, and (S)-13g were solved by Patterson methods using DIRDIF92 [42], which
revealed the positions of the Br-atom. All remaining non-H atoms were located in Fourier
expansions of the Patterson solution. Structures (S)-2d, (S)-2e, (S)-13f, (R)-6c, and (R)-7c
were solved by direct methods, which revealed the positions of all non-H atoms.
                                                 
4) CCDC-670070 – 670078 contain the supplementary crystallographic data for this paper.
These data can be obtained free of charge from the Cambridge Crystallographic Data
Centre via http://www.ccdc.cam.ac.uk/data_request/cif.
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In 13a, the asymmetric unit contains one peptide molecule plus a site partially
occupied by a H2O molecule. The O-atom of the H2O molecule has a site occupation factor
of approximately 0.33. H-atom positions were not defined for the water molecule. The
isobutyl group is disordered. Two sets of positions were defined for each of the atoms of
this group and the site occupation factor of the major conformation of this group refined to
0.519(4). Similarity restraints were applied to the chemically equivalent bond lengths and
angles involving all disordered C-atoms, while neighboring atoms within and between each
conformation of the disordered group were restrained to have similar atomic displacement
parameters. In 13b, the isobutyl group is also disordered and was modelled analogously to
13a; the site occupation factor of the major conformation refined to 0.629(6). In (S)-2e, the
five-membered ring is disordered over two conformations. Two positions were defined for
atom C(33) of this ring and the site occupation factor of the major conformation refined to
0.55(1). Similarity restraints were applied to the C–C bond lengths involving the
disordered atom. In (S)-13f, there are two symmetry-independent molecules in the
asymmetric unit. The atomic coordinates of the two molecules were tested carefully for a
relationship from a higher symmetry space group using the program PLATON [43], but
none could be found. Disorder is present in the isobutyl substituents at C(2) of molecule A,
and C(42) and C(48) of molecule B. Two positions were defined for the two terminal Me
groups and the methine C-atom of each disordered group, but in some cases, particularly at
C(2) and C(48), the behavior of the refinement suggested that the atoms of these groups
adopt several orientations which results in the electron density in these regions being
smeared out. Restraints were applied to the bond lengths and the anisotropic displacement
parameters of the disordered atoms. The site occupation factors of the major conformations
refined to values ranging from 0.505(9) [group at C(2)] to 0.66(1) [group at C(42)]. In (S)-
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13g, the asymmetric unit contains one molecule of the peptide and two molecules of
MeOH.
The non-H atoms were refined anisotropically, except for atom C(6) in (S)-13g,
which was refined isotropcially. The hydroxy H-atoms, where present, and the amide H-
atoms, except for those in 13a and (S)-13f, were placed in the positions indicated by
difference electron density maps and their positions were allowed to refine together with
individual isotropic displacement parameters. All remaining H-atoms in the structures were
placed in geometrically calculated positions and refined using a riding model where each
H-atom was assigned a fixed isotropic displacement parameter with a value equal to 1.2Ueq
of its parent C-atom (1.5Ueq for the Me groups). The refinement of each structure was
carried out on F2 using full-matrix least-squares procedures, which minimized the function
Σw(Fo
2 – F2)2. Corrections for secondary extinction were applied, except for 13a and (S)-
13g . The crystals of each compound were enantiomerically pure and the absolute
configuration was determined experimentally for 13a, 13b, (S)-13f, and (S)-13g (absolute
structure paramters [44] of –0.005(8), –0.012(10), 0.004(5), and –0.003(11), resp.). The
absolute configurations of the other compounds could not be determined, as no atoms
exhibiting significant anomalous scattering are present. In these latter cases, the
enantiomer used in each refinement was based on the known configuration derived from
the synthetic precursors of the molecule.
Neutral atom scattering factors for non-H atoms were taken from [45], and the
scattering factors for H-atoms were taken from [46]. Anomalous dispersion effects were
included in Fcalc [47]; the values for f ' and f " were those of [48]. The values of the mass






[1] J.-P. Obrecht, P. Schönholzer, C. Jenny, R. Prewo, H. Heimgartner, Helv. Chim. Acta
1988, 71, 1319.
[2] a) R. S. Rathore, Biopolymers 2005, 80, 651; b) M. Hanyu, T. Murashima, T.
Miyazawa, T. Yamada, Tetrahedron Lett. 2004, 45, 8871; c) J.-P. Mazaleyrat, K.
Wright, A. Gaucher, N. Toulemonde, M. Wakselman, S. Oancea, C. Peggion, F.
Formaggio, V. Setnicka, T. A. Keiderling, C. Toniolo, J. Am. Chem. Soc. 2004, 126,
12874.
[3] C. Toniolo, H. Brückner, ‘Topical Issue Peptaibiotics’, in Chem. Biodiv. 2007, 4,
1021–1412; ‘The Peptaibol Database’, http://www.cryst.bbk.ac.uk/peptaibol.
[4] C. Toniolo, E. Benedetti, ICI Atlas of Science: Biochemistry 1988, 1, 225; C.
Toniolo, E. Benedetti, Trends Biochem. Sci. 1991, 16, 350.
[5] a) J. M. Humphrey, A. R. Chamberlin, Chem. Rev. 1997, 97, 2243; b) T. Butters, P.
Huetter, G. Jung, N. Pauls, H. Schmitt, G. M. Sheldrick, W. Winter, Angew. Chem.
Int. Ed. Engl. 1981, 20, 889; c) E. Katz, G. Jung, M. Aydin, N. Lucht, W. A. König,
T. Ooka, Liebigs Ann. Chem. 1985, 1041; d) I. L. Karle, M. A. Perozzo, V. K.
Mishra, P. Balaram, Proc. Natl. Acad. Sci. USA 1998, 95, 5501; e) R. Gessmann, P.
Benos, H. Brückner, M. Kokkinidis, J. Pept. Sci. 1999, 5, 83; f) R. T. N. Luykx, A.
55
Linden, H. Heimgartner, Helv. Chim. Acta 2003, 86, 4093; g) N. Pradeille, O. Zerbe,
K. Moehle, A. Linden, H. Heimgartner, Chem. Biodiv. 2005, 2, 1127.
[6] E. Mossel, F. Formaggio, M. Crisma, C. Toniolo, Q. B. Broxterman, W. H. J.
Boesten, J. Kamphuis, P. J. L. M. Quaedflieg, P. Temussi, Tetrahedron: Asymmetry
1997, 8, 1305; M. Horikawa, Y. Shigeri, N. Yumoto, S. Yoshikawa, T. Nakajima, Y.
Ohfume, Bioorg. Med. Chem. Lett. 1998, 8, 2027; B. A. Wallace, Bioessays 2000,
22, 227; P. A. Grigoriev, A. Berg, B. Schlegel, S. Heinz, U. Gräfe, J. Antibiot. 2002,
55, 826.
[7] W. Hauke, C. Methfessel, H. U. Wilmsen, E. Katz, G. Jung, G. Boheim, Biochem.
Biophys. Acta 1983, 727, 108; M. K. Das, S. Raghothama, P. Balaram, Biochemistry
1986, 25, 7110; K. Dornberger, W. Ihn, M. Ritzau, U. Gräfe, B. Schlegel, W. F.
Fleck, J. W. Metzger, J. Antibiot. 1995, 48, 977.
[8] Y. Fu, L. G. J. Hammarström, T. J. Miller, F. R. Fronczek, M. L. McLaughlin, R. P.
Hammer, J. Org. Chem. 2001, 66, 7118; J.-F. Lohier, K. Wright, C. Peggion, F.
Formaggio, C. Toniolo, M. Wakselman, J.-P. Mazaleyrat, Tetrahedron 2006, 62,
6203; D. Obrecht, C. Spiegler, P. Schönholzer, K. Müller, H. Heimgartner, F. Stierli,
Helv. Chim. Acta 1992, 75, 1666; D. Obrecht, C. Albrecht, M. Altorfer, U. Bohdal,
A. Grieder, M. Kleber, D. Pfyffer, K. Müller, Helv. Chim. Acta 1996, 79, 1315.
[9] H. Brückner, A. Koza, Amino Acids 2003, 24, 311; J. R. Spencer, V. V. Antonenko,
N. G. J. Delaet, M. Goodman, Int. J. Pept. Protein Res. 1992, 40, 282; C. Auvin-
Guette, E. Frérot, J. Coste, S. Rebuffat, P. Jouin, B. Bodo, Tetrahedron Lett. 1993,
34, 2481; A. Ogrel, W. Bloemhoff, J. Lugtenburg, J. Raap, Liebigs Ann. Recl. 1997,
41; C. Piazza, F. Formaggio, M. Crisma, C. Toniolo, J. Kamphuis, B. Kaptein, Q. B.
Broxterman, J. Pept. Sci. 1999, 5, 96.
56
[10] U. Slomczynska, D. D. Bensen, M. T. Leplawy, G. R. Marshall, J. Am. Chem. Soc.
1992, 114, 4095; U. Slomczynska, J. Zabrocki, K. Kaczmarek, M. T. Leplawy, D. D.
Bensen, G. R. Marshall, Biopolymers 1992, 32, 1461.
[11] H. Wenschuh, M. Beyermann, E. Krause, M. Brudel, R. Winter, M. Schürmannn, L.
A. Carpino, M. Bienert, J. Org. Chem. 1994 , 59 , 3275; H. Wenschuh, M.
Beyermann, H. Haber, J. K. Seydel, E. Krause, M. Bienert, J. Org. Chem. 1995, 60,
405; L. A. Carpino, M. Beyermann, H. Wenschuh, M. Bienert, Acc. Chem. Res.
1996, 29, 268.
[12] P. Wipf, H. Heimgartner, Helv. Chim. Acta 1986, 69, 1153; H. Heimgartner, Angew.
Chem. 1991, 103, 271.
[13] a) P. Wipf, H. Heimgartner, Helv. Chim. Acta 1990, 73, 13; b) W. Altherr, H.
Heimgartner, in ‘Peptides 1990’, Eds. E. Giralt, D. Andreu, ESCOM, Leiden, 1991,
p. 107; c) W. Altherr, H. Heimgartner, in ‘Peptides 1992’, Eds. C. H. Schneider, A.
N. Eberle, ESCOM, Leiden, 1993, p. 387; d) N. Pradeille, H. Heimgartner, J. Pept.
Sci. 2003, 9, 827; e) W. Altherr, A. Linden, H. Heimgartner, Chem. Biodiv. 2007, 4,
1144.
[14] P. Wipf, H. Heimgartner, Helv. Chim. Acta 1988, 71, 258; M. Sahebi, P. Wipf, H.
Heimgartner, Tetrahedron 1989, 45, 2999.
[15] a) J. M. Villalgordo, H. Heimgartner, Tetrahedron 1993, 49, 7215; b) C. Strässler, A.
Linden, H. Heimgartner, Helv. Chim. Acta 1997, 80, 1528; c) S. Stamm, A. Linden,
H. Heimgartner, Helv. Chim. Acta 2003, 86, 1371.
[16]  R. Luykx, C. B. Bucher, A. Linden, H. Heimgartner, Helv. Chim. Acta 1996, 79,
527; G. Suter, S. S. Stoykova, A. Linden, H. Heimgartner, Helv. Chim. Acta 2000,
83, 2961; R. A. Breitenmoser, T. R. Hirt, R. T. N. Luykx, Helv. Chim. Acta 2001, 84,
57
972; R. A. Breitenmoser, H. Heimgartner, Helv. Chim. Acta 2002, 85, 885; J. L.
Räber, K. A. Brun, H. Heimgartner, Heterocycles 2007, 74, in press; M. Löpfe, A.
Linden, H. Heimgartner, in preparation.
[17] C. B. Bucher, A. Linden, H. Heimgartner, Helv. Chim. Acta 1995, 78, 935.
[18] C. B. Bucher, H. Heimgartner, Helv. Chim. Acta 1996, 79, 1903.
[19] K. A. Brun, A. Linden, H. Heimgartner, Helv. Chim. Acta 2001, 84, 1756.
[20] C. K. Johnson, 'ORTEP II – Report ORNL-5138', Oak Ridge National Laboratory,
Oak Ridge, Tennessee, 1976.
[21] J. Bernstein, R. E. Davis, L. Shimoni, N.-L. Chang, Angew. Chem., Int. Ed. 1995, 34,
1555.
[22] K. A. Brun, A. Linden, H. Heimgartner, Helv. Chim. Acta 2002, 85, 3422.
[23] C. Toniolo, E. Benedetti, Trends Biochem. Sci. 1991, 16, 350.
[24] V. Pavone, B. Di Blasio, A. Santini, E. Benedetti, C. Pedone, C. Toniolo, M. Crisma,
J. Mol. Biol. 1990, 214, 633.
[25] N. Shamala, R. Nagaraj, P. Balaram, J. Chem. Soc., Chem. Commun. 1978, 996.
[26] B. Di Blasio, A. Santini, V. Pavone, C. Pedone, E. Benedetti, V. Moretto, M. Crisma,
C. Toniolo, Struct. Chem. 1991, 2, 523.
[27] M. Vlassi, H. Brueckner, M. Kokkinidis, Acta Crystallogr., Sect. B 1993, 49, 560.
[28] C. Toniolo, G. M. Bonora, A. Bavoso, E. Benedetti, B. Di Blasio, V. Pavone, C.
Pedone, Macromolecules 1986, 19, 472.
[29] C. Toniolo, G. M. Bonora, V. Barone, A. Bavoso, E. Benedetti, B. Di Blasio, P.
Grimaldi, F. Lelj, V. Pavone, C. Pedone, Macromolecules 1985, 18, 895.
[30] R. Bardi, A. M. Piazzesi, C. Toniolo, P. Balaram, Biopolymers 1986, 25, 1635.
58
[31] A. Santini, B. Di Blasio, S. Galdiero, R. Iacovino, C. Pedone, E. Benedetti, M.
Crisma, C. Toniolo, Z. Kristallogr. 1996, 211, 616.
[32] C. Toniolo, M. Crisma, G. M. Bonora, B. Klajc, F. Lelj, P. Grimaldi, A. Rosa, S.
Polinelli, W. H. J. Boesten, E. M. Meijer, H. E. Schoemaker, J. Kamphuis, Int. J.
Pept. Protein Res. 1991, 38, 242.
[33] A. Aubry, B. Bayeul, G. Précigoux, M. Pantano, F. Formaggio, M. Crisma, C.
Toniolo, W. H. J. Boesten, H. E. Schoemaker, J. Kamphuis, J. Chem. Soc., Perkin
Trans. 2 1994, 525.
[34] C. Toniolo, M. Crisma, F. Formaggio, G. Valle, G. Cavicchioni, G. Precigoux, A.
Aubry, J. Kamphuis, Biopolymers 1993, 33, 1061.
[35] C. Toniolo, F. Formaggio, M. Crisma, G. M. Bonora, S. Pegoraro, S. Polinelli, W. H.
J. Boesten, H. E. Schoemaker, Q. B. Broxterman, J. Kamphuis, Pept. Res. 1991, 5,
56.
[36] M. Pantano, F. Formaggio, M. Crisma, G. M. Bonora, S. Mammi, E. Peggion, C.
Toniolo, W. H. J. Boesten, Q. B. Broxterman, H. E. Schoemaker, J. Kamphuis,
Macromolecules 1993, 26, 1980.
[37] F. Formaggio, M. Crisma, G. M. Bonora, M. Pantano, G. Valle, C. Toniolo, A.
Aubry, D. Bayeul, J. Kamphuis, Pept. Res. 1995, 8, 6.
[38] P. Wipf, Dissertation, Universität Zürich, 1987.
[39] M. Sahebi, Diplomarbeit, Universität Zürich, 1987.
[40] A. C. T. North, D. C. Phillips, F. S. Mathews, Acta Crystallogr., Sect. A 1968, 24,
351.
[41] P. Coppens, L. Leiserowitz, D. Rabinovich, Acta Crystallogr. 1965, 18, 1035.
59
[42] P. T. Beurskens, G. Admiraal, G. Beurskens, W. P. Bosman, S. Garcia-Granada, J.
M. M. Smits, C. Smykalla, 'DIRDIF-92. The DIRDIF program system. Technical
Report of the Crystallography Laboratory', University of Nijmegen, The Netherlands,
1992.
[43] A. L. Spek, J. Appl. Crystallogr. 2003, 36, 7.
[44] H. D. Flack, Acta Crystallogr., Sect. A 1983, 39, 876; G. Bernardinelli, H. D. Flack,
Acta Crystallogr., Sect. A 1985, 41, 500.
[45] E. N. Maslen, A. G. Fox, M. A. O'Keefe, in 'International Tables for
Crystallography', Ed. A. J. C. Wilson, Kuwer Academic Publishers, Dordrecht, 1992,
Vol. C, Table 6.1.1.1, p. 477.
[46] R. F. Stewart, E. R. Davidson, W. T. Simpson, J. Chem. Phys. 1965, 42, 3175.
[47] J. A. Ibers, W. C. Hamilton, Acta Crystallogr. 1964, 17, 781.
[48] D. C. Creagh, W. J. McAuley, in 'International Tables for Crystallography', Ed. A. J.
C. Wilson, Kluwer Academic Publishers, Dordrecht, 1992, Vol. C, Table 4.2.6.8, p.
219.
[49] D. C. Creagh, J. H. Hubbell, in 'International Tables for Crystallography', Ed. A. J.
C. Wilson, Kluwer Academic Publishers, Dordrecht, 1992, Vol. C, Table 4.2.4.3, p.
200.
[50] G. M. Sheldrick, 'SHELXL97, Program for the Refinement of Crystal Structures',
University of Göttingen, Germany, 1997.
[51] G. M. Sheldrick, 'SHELXS97, Program for the Solution of Crystal Structures',
University of Göttingen, Germany, 1997.
[52] A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, M. C. Burla, G. Polidori,
M. Camalli, SIR92, J. Appl. Crystallogr. 1994, 27, 435.
60
Legends
Fig. 1. ORTEP Plots [20] of the molecular structures of a) (R)-6c (Z-Leu-Aib-(R)-
Iva-OH), b) (R)-7c (Z-Leu-Aib-(R)-Iva-NHMe), and c) (R)-7d (Z-Leu-Aib-(R)-Val(2Me)-
NHMe) (50% probability ellipsoids; arbitrary numbering of the atoms)
Fig. 2. ORTEP Plots [20] of the molecular structures of a) 13a (pBrBz-Leu-Aib-Aib-
Gln-Valol), b) 13b (pBrBz-Leu-Aib-Ac5c-Gln-Valol), c) (S)-2d (Z-Leu-Aib-(S)-Val(2Me)-
Gln-Valol), d) (S)-2e (Z-Leu-Aib-(S)-Ala(2cPent)-Gln-Valol), e) one of the two symmetry-
independent molecules of (S)-13f (pBrBz-Leu-Aib-(S)-Leu(2Me)-Gln-Valol), and f) (S)-
13g  (pBrBz-Leu-Aib-(S)-Phe(2Me)-Gln-Valol) (50% probability ellipsoids; arbitrary
numbering of the atoms; any solvent molecules and minor disorder components have been
omitted for clarity)
Fig. 3. Temperature dependence of the signals of the amide H-atoms of (S)-2g
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Table 1. Synthesis of the Tripeptide Amides 3 from Dipeptide 5
Xaa Azirine
1
R1, R2 R3, R4 Tripeptide Amide 3
Yield [%]
Aib 1a Me, Me Ph, Me 3a 95
Ac5c 1b –(CH2)4– Ph, Me 3b 97
(2S)-1c
1c
Me, Et NaphthEt, Me (S)-3c 77 [19](S)-Iva
(2S)-1i Me, Et PhEt, Me (S)-3i 93 [18]
(2R)-1c Et, Me NaphthEt, Me (R)-3c 83 [19](R)-Iva
(2R)-1i Et, Me PhEt, Me (R)-3i 91 [18]
(S)-Val(2Me) (2S)-1d iPr, Me NaphthEt, Me (S)-3d 67 [19]
(R)-Val(2Me) (2R)-1d Me, iPr NaphthEt, Me (R)-3d 69 [19]
(S)-Ala(2cPent) (2S)-1e cPent, Me NaphthEt, Me (S)-3e 39 [19]
(R)-Ala(2cPent) (2R)-1e Me, cPent NaphthEt, Me (R)-3e 38 [19]
(S)-Leu(2Me) (2S)-1f iBu, Me NaphthEt, Me (S)-3f 64 [19]
(R)-Leu(2Me) (2R)-1f Me, iBu NaphthEt, Me (R)-3f 60 [19]
(S)-Phe(2Me) (2S)-1h Bn, Me 'Prolinol' (S)-3h 70
(2S)-1g Bn, Me NaphthEt, Me (S)-3g 59 [19]
(R)-Phe(2Me) (2R)-1h Me, Bn 'Prolinol' (R)-3h 79
(2R)-1g Me, Bn NaphthEt, Me (R)-3g 62 [19]
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Table 2. Synthesis of the Model Pentapeptides 2 and 13 from Tripeptide Amides 3














Ph, Me 6a 88 2a 77 13a 78
Ac5c –(CH2)
4–
Ph, Me 6b 90 2b 87 13b 85
Me, Et NaphthEt,
Me
(S)-6c 37 (S)-7c 30(S)-Iva





(R)-6c 39 (R)-7c 29(R)-Iva
PhEt, Me (R)-6i 84 (R)-2i 75 [18]
(S)-Val(2Me) iPr, Me NaphthEt,
Me
(S)-6d 65 (S)-7d 21 (S)-2d 37
(R)-Val(2Me) Me, iPr NaphthEt,
Me



































Table 3. Torsion Angles of the First β-Turn (Amino Acids i, i + 1, i + 2, and i + 3)
φi + 1 [°] ψi + 1 [°] φi + 2 [°] ψi + 2 [°] type of β-turn
13a –56.7(6) –42.7(6) –57.0(6) –31.5(5) III
13b –54.9(7) –40.2(7) –58.2(7) –32.3(6) III
(S)-2d –49.6(2) –44.6(1) –58.9(1) –24.9(1) III
(S)-2e –51.3(2) –43.3(2) –60.1(2) –23.1(2) III
(S)-13f mol. A –54.8(4) –43.1(3) –62.7(3) –26.5(3) III
(S)-13f mol. B –54.3(4) –42.9(4) –59.7(4) –28.6(4) III
(S)-13g –53.2(6) –44.2(6) –54.6(7) –37.1(7) III
64
Table 4. Torsion Angles of the Second β-Turn (Amino Acids i + 1, i + 2, i + 3, and i + 4)
φi + 2 [°] ψi + 2 [°] φi + 3 [°] ψi + 3 [°] type of β-turn
13a –57.0(6) –31.5(5) –78.7(5) –4.0(5) I
13b –58.2(7) –32.3(6) –78.3(6) –5.0(7) I
(S)-2d –58.9(1) –24.9(1) –77.1(1) –1.0(2) I
(S)-2e –60.1(2) –23.1(2) –76.8(2) –2.0(2) I
(S)-13f mol. A –62.7(3) –26.5(3) –75.6(3) –9.3(4) I
(S)-13f mol. B –59.7(4) –28.6(4) –76.8(4) –8.3(4) I
(S)-13g –54.6(7) –37.1(7) –71.7(7) –28.1(8) III
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Table 5. Temperature Coefficients of the Signals of the Amide H-Atoms of (S)-2g
Amide Protons [Hz/K] [10–3 ppm/K]
NH of Leu –6.77 –2.26
NH of Aib –5.54 –1.85
NH of Phe(2Me) not observed not observed
NH of Gln –0.96 –0.32
NH of Valol –1.53 –0.51
NH(1) of Gln Side Chain –3.25 –1.08
NH(2) of Gln Side Chain –1.27 –0.42
